WO2005046790A2 - Stimulateur cardiaque orthorythmique inotrope - Google Patents
Stimulateur cardiaque orthorythmique inotrope Download PDFInfo
- Publication number
- WO2005046790A2 WO2005046790A2 PCT/FR2004/002767 FR2004002767W WO2005046790A2 WO 2005046790 A2 WO2005046790 A2 WO 2005046790A2 FR 2004002767 W FR2004002767 W FR 2004002767W WO 2005046790 A2 WO2005046790 A2 WO 2005046790A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stimulation
- burst
- heart
- pulse
- zone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
Definitions
- the subject of the invention is an electrical stimulation device for the heart making it possible, in particular, to improve hemodynamic performance, that of the cells of the heart and in particular the blood flow, and this in particular in patients suffering from heart failure, or tachycardia or arrhythmia, and in particular severe or acute heart failure, left or right, systolic or diastolic or global.
- the invention also relates to a method for controlling such a device.
- the subject of the invention is also a method of electrical stimulation of the heart as well as the cellular improvement of the heart using such a device, in particular in the patient suffering from heart failure, or from tachycardia or arrhythmia, and in particular acute heart failure, left, right, or global.
- the devices for automatic stimulation of the heart are essentially intended to replace or regulate the spontaneous electrogenesis of activation of the heart muscle.
- An important step has been taken for the control and reduction of isolated tachycardias, tachyarrhythmias or extrasystoles in the methods and devices described in the Zacouto patents US-A-4,052,991 and US-A-3, 857,399.
- These improvements made it possible, in particular, to modify the coupling intervals of the electrical stimulation as a function of the variable duration of the previous cycle or cycles, for example according to a percentage of this duration.
- These improvements also made it possible to send bursts of bursts and ramps. They also allowed differential marking of local detection and stimulation spots on the EKG.
- Paired (STP) or coupled (STC) and optimal inotropic (STIO) stimulation tries to manually or automatically provoke a periodic succession of inhibitions and myocardial stimulations with, preferably, parameters allowing maximum hemodynamics and protection. antiarrhythmic.
- the STIO allows, in principle, a stronger mobilization of the energy reserves and acquisitions of the myocardium generally the larger the more it is tired (Wayne Cooper: Postextrasystolic Potentialisation, Circulation, vol 88, n ° 6, 2962, Dec 1993) such as, for example, the increased activation of a cycle of pentoses in addition to the cycle of Krebs (hexoses) and / or a reinforced and resynchronized activation of certain ion channels and transmembrane electrons, the increase in concentrations and intracellular releases of calcium ions, secretions of vaso- or myoactive peptides and modifications of certain expressions, translations and local genetic transductions d 'adaptations to an enhanced biochemical myocardial energy of
- RPE post-extrasystolic reinforcement
- the devices currently used do not allow, by electrical stimulation, to durably improve the hemodynamic performance of the heart muscle, this in particular in patients where this performance is significantly lowered, especially in patients with severe heart failure.
- the depositor had been able to obtain, in two patients with acute left ventricular insufficiency, a temporary improvement in hemodynamics by managing to couple, after manual start-up adjustment, paired stimulation comprising bursts of pulses of consecutive stimulations brought together in the same coupled cardiac cycle, on the R wave, towards the end of the refractory zone (F Zacouto et al.; Paris, Nouv.
- the present invention proposes, and this against the discouraging difficulties and conclusions of research, to provide a device and methods allowing a lasting and significant improvement in the hemodynamic performance of the heart by electrical stimulation.
- Another objective of the invention is to treat arrhythmias or tachycardias, including recurrent or non-rapidly reducible tachycardias by antitachycardial pacemakers (Zacouto, US-3,857,399 and US-4,052,991), including in patients with insufficiency and instantly improve hemodynamics, whether or not the tachycardia is reduced.
- the invention proposes to perfect a device for stimulating the heart muscle allowing a significant increase in the hemodynamic performance of the heart and / or the treatment of tachycardias
- a device preferably implanted permanently comprising: - means of automatic acquisition of the heart rate, making it possible in particular to know the interval between at least the last two R waves (provoked or spontaneous) of the cardiac cycle which has just ended, - means making it possible to determine, preferably in real time, the duration of the electrical refractory period (ZRE) which follows the last R wave of said cycle, - and means for addressing, substantially without delay towards or at the end of said refractory period (ZRE), at least one stimulation pulse.
- ZRE electrical refractory period
- An object of the invention is a device for stimulating and / or strengthening the heart muscle and / or myocardial cells allowing a significant increase in the hemodynamic performance of the heart and / or the treatment of tachycardias, tachyarrhythmias or atrial fibrillations, comprising: means for automatic acquisition of the heart rate, and optionally its origin, making it possible in particular to know the interval between at least the last two R waves (provoked or spontaneous) of the cardiac cycle which has just ended, - means of acquisition of cardiac hemodynamics, - means of determining, continuously in real time, the duration of the electrical refractory period (ERZ) following the last R wave of said cycle, - means of evaluating at least one parameter relating to the cellular functional state of the myocardi
- said evaluation means determine an effective critical zone to target ZCE, which is placed immediately after the end of the electrical refractory zone, and ends at the end of a refractory zone of maximum myocardial contraction ZRMM, l sending of said stimulation pulse intervening in said ZCE zone, if it is present and targetable, and does not cause intractable arrhythmias.
- means for automatically reversing, for example, from 20 ms to 20 ms, the ZCE zone are provided, while monitoring the hemodynamics and metabolic consumption of the myocardium.
- said evaluation means try to detect or verify at each cycle the threshold of excitation of the myocardium.
- the device is arranged to determine at each cycle, and preferably in real time, the duration of said electrical refractory period (ZRE).
- the determination of the refractory zone is carried out in a part of the heart in which the pulse or the burst of stimulation is addressed, for example using the same electrodes for detection and stimulation, or very close electrodes.
- a burst of stimulation pulses is sent, substantially towards the end of said refractory period (ZRE), the duration of the burst and the repetition interval of said pulses being such that a pulse of stimulation of the burst is addressed to the heart substantially immediately after the end of said refractory period.
- the stimulating pulse addressed towards or at the end of the refractory period is addressed, almost without delay, for example between 10 and
- the device is thus capable of performing optimal inotropic paired or coupled stimulation, hereinafter called STIO.
- STIO optimal inotropic paired or coupled stimulation
- the percentage will be 25 to 30% for a rate of 60 p / min and 50 to 80% for a rate of 120 p / min.
- the duration of the refractory zone can be evaluated by any other means already known to cardiologists, for example by progressive scanning of an electrical pulse in a delayed burst, from cycle to cycle until the acquisition of a electrosystole generated.
- the ZRE duration obtained can then be used during one or during the following cycles for sending the pulse or the burst of stimulation pulses.
- the means (4) for determining the duration of the refractory zone are arranged to acquire, by scanning a second pulse, the duration substantially exact of the refractory zone, this scanning being carried out for example during the previous or ongoing cardiac cycles. If a burst of stimulation pulses is used, it will preferably start a little before the estimated end of the ZRE refractory period and the duration of this burst and, consequently, the number of pulses of stimulation will advantageously be such that a stimulation pulse can intervene very quickly after the end of said refractory period.
- These means of determining the duration of a refractory zone of the heart are known to cardiologists.
- the device in the case where stimulation at the end of the ZRE refractory period is carried out by sending a burst of pulses, can send the burst substantially before the estimated end of the refractory period ZRE, and detect without delay, in the same cycle, preferably at the same location of the heart, which of the burst pulses causes an electrosystole R ', for a given stimulating amplitude, which provides the duration ZRE which has just elapsed .
- This detected duration also makes it possible to determine the probable duration of the ZRE refractory zone of the following cycle.
- the myocardium may undergo a metabolic change. which can either precede a serious arrhythmia if the ERZ decreases, or a functional recovery if the ERZ becomes longer.
- the device monitors and differentiates these two cases and reacts instantly according to a schedule. For example, in the event of a serious arrhythmia, the stimulation is stopped or the stimulation parameters are modified.
- the burst of stimulation pulses may be advanced or moved back with respect to an estimate of the refractory zone, and / or the interval between the pulses in the burst and / or the amplitude of the pulses decreased or increased, the device having automatic acquisition means, in particular by obtaining the intracardiac ECG making it possible to determine which is the stimulation pulse in the burst which triggered the R ′ wave, and, consequently, possibly to modify the burst.
- Such a device will be particularly indicated for reducing tachycardias, including sinus tachycardias of patients with heart failure.
- the device comprises means sensitive to spontaneous or stimulated R waves and / or to the determination of the electrical and mechanical refractory zones, in particular by scanning the entire burst or only inside this burst and / or means for determination without delay of the excitability thresholds of the heart, for example by providing stimulation pulses of variable intensity, including sub-thresholds to allow their measurement. It is also planned to be able to control the pacemaker as a conventional anti-tachycardia orthorythmic stimulator and reacting to extrasystoles and to be able to stop automatically programmed STIO in the event of excessive hemodynamic instability.
- the device is characterized by the fact that it further comprises means for very precise acquisition of the cardiac hemodynamics.
- These means are, in themselves, known and preferably comprise one or more intracardiac pressure sensors or such sensors arranged close by.
- a device according to the invention may comprise, in addition to the means for acquiring rhythm, the means for determining the duration of the refractory zone and the means for sending a pulse or a burst, as described above, means sensitive to the precise acquisition of hemodynamics to determine the variations in hemodynamic efficiency, these means being capable of controlling the sending and optionally the parameters of the pulse or of the burst and / or the application of a dose of drug infused externally controlled or from an implanted drug reservoir until a degree of hemodynamic performance is obtained , for example programmed or determined in advance, or in a manner close to that which produced the most favorable hemodynamics for the patient at a given time.
- a continuous monitoring of the excitability threshold of the heart is carried out by means of a periodic decrease in the stimulating energy used in accordance with Zacouto patent FR-A1-1,237,702, PV 651,632 of July 11, 1953 and allowing an instant readjustment of the stimulation parameters.
- One way to do this may be to gradually or suddenly decrease the stimulating pulse from the pulse train until the pulse is picked up. During periods when this impulse remains ineffective, the impulse that follows it in its train takes control of the heart.
- the STIO can be programmed to initiate stimulation, for example, at reduced amplitude, which also reduces the risk of causing extrasystoles.
- We can also, for example, reduce by a third the amplitude close to the threshold of the first three or four pulses of a train comprising six or eight pulses to observe whether or not this targeted sub-threshold stimulation promotes the threshold of excitability myocardial. If this threshold is lowered, this "facilitation" can be quantified, for example, as a percentage of decreasing amplitude and, by repeating this examination periodically, measure its duration of facilitation.
- a withdrawal of the stimulating impulse or of the entire stimulation train will trigger an instantaneous increase in the energy amplitude of the impulse that has become sub-limit or of the whole stimulating train of the next cardiac cycle.
- a pulse ramp with gradually increasing voltage in order to determine, by automatic measurement within each cardiac cycle, for the program of the inotropic orthorhythmic software, the new myocardial excitability threshold. at from which a new process of control and intervention on the amplitude of the stimulating impulses will start.
- the STIO achieves an optimal permanent instant adaptation of the stimulating intensities according to their coupling intervals with respect to the previous R wave, whether it is a decrease as well as a spontaneous increase in the excitability thresholds. myocardium.
- the device comprises means for giving an impulse intended for electrical stimulation, an amplitude greater by at least 30%, and preferably between 30% and 90% of the amplitude of the last observed infra-secondary pulse.
- the parameters on which the device acts can be simply a programmed ventricular rhythm and / or an automatic adjustment of the beginning or the end or the duration of the burst or the number or the characteristics (in particular width, polarity, intensity) of the pulses in the salvo, or even a location of the sending of the salvo on different stimulation electrodes. For example, you can gradually reduce a single-pulse burst. For this, one can periodically feel with, at least, a second pulse which progressively moves by, for example, 25 ms in front of the stimulating pulse and then moves back step by step, for example by 4 m / s in each cycle , to automatically measure the start of the non-refractory zone.
- this impulse When the exploratory impulse recedes towards the stimulating impulse, this impulse itself is made to recede until the start of the decrease in the ventricular pressure / volume curve or the increase in oxygen consumption or secretion is obtained and membrane accumulation of electrons or, for example, of proximal catecholamines or lactic acid, this position corresponding to exceeding the end of the mechanical refractory zone with maximum active contraction known as ZRMM.
- ZRMM maximum active contraction
- the electrical stimulation of the heart according to the invention makes it possible to obtain, at each cardiac cycle (CC), an optimal inotropic paired (STP) or coupled (STC) stimulation (STIO) by very precise adjustments of the pulses relative to the refractory functional zones.
- electrical (ZRE) and myocardial (ZRM) and to the corresponding metabolic reactions and in space with respect to the cardiac locations of the electrodes allowing to obtain the best hemodynamics, or antiarrhythmic efficacy.
- These functional areas can vary significantly with each cycle, especially in case of myocardial suffering.
- these zones can be analyzed continuously and in real time thanks, for example, to the means described in the US Zacouto patents No.
- the device may include means for progressively reducing a burst to a single or a small number of pulses, in particular by periodically feeling with, at least, a second pulse which progressively moves in front of the stimulating pulse to automatically measure the start of the non-refractory zone, so that, when the exploratory pulse recedes towards the stimulating pulse, the latter can be retracted, in particular periodically in the event of instability of the operation until the start of the decrease in the pressure curve / ventricular volume or increase in oxygen consumption or a corresponding parameter, in particular the membrane secretion of electrons, local pH or ketone bodies, this position corresponding to exceeding the end of the mechanical refractory zone at maximum contraction ( ZRMM).
- ZRMM maximum contraction
- the device can include means for switching from paired stimulation to coupled stimulation, that is to say at a fully stimulated rhythm, said means being sensitive to the means of acquiring the electrocardiogram and / or hemodynamics, and / or myocardial metabolism.
- Instant inhibition of extrasystoles or arrhythmias during STIO The device according to the invention can also be arranged to treat extrasystoles and arrhythmias which can appear, either spontaneously or under the effect of the functioning of the device.
- a condition for the proper functioning of STIO is to instantly detect the early extrasystoles that can follow or accompany a pulse train and also react instantly by causing stimulation or a stimulation train from the start of detection of such a extrasystole.
- the instantaneous detection of an early extrasystole requires an ECG recording, preferably independent of its directional intramyocardial propagation which is slow (1 m / sec) before arriving at the intracardiac detector electrode.
- ECG recording preferably independent of its directional intramyocardial propagation which is slow (1 m / sec) before arriving at the intracardiac detector electrode.
- the antiarrhythmic program will instantly trigger a stimulation, preferably in bursts, from all the stimulating electrodes available in order to immediately cause a fusion complex between the propagations of the stimulated and extrasystolic depolarizations.
- This fusion complex will block the spread of extrasystolic depolarization and will often allow the suppression of premature myocardial ectopias. It is also possible, when especially repeated early myocardial ectopias threaten the effectiveness of STIO, to instantly and temporarily shorten the diastoles to close the non-refractory intervals of the cardiac cycles during which the initiation of early extrasystoles can occur.
- the device according to the invention can comprise a plurality of electrodes arranged at different locations of the heart muscle and / or at a distance from the heart and the acquisition means. sensitive to electrical signals appearing on and away from the electrodes to note, at an early stage, the occurrence of an electrical extrasystole in a myocardial area close to those of electrodes initially affected.
- the means making it possible to address the stimulation pulses are then made sensitive to such a finding in order to instantaneously emit in a nearby electrode or in a plurality of electrodes, a stimulation pulse or burst whose electrical propagation in the myocardium is directed towards the myocardial area affected by extrasystole, and cause a fusion complex between them which can block the spread of extrasystole.
- the device is preferably connected to a plurality of electrodes, such as electrodes at the level of the coronary sinus, the electrodes of the septum and the ventricular free walls, and preferably juxtacardiac, extracardiac or intracavitary electrodes, the device being arranged so that the acquisition means detect the electrode near which the extrasystole is originating, the means for sending a stimulation pulse or a burst being arranged to address the stimulation at least from an electrode distant from the origin of the extrasystole.
- electrodes such as electrodes at the level of the coronary sinus, the electrodes of the septum and the ventricular free walls, and preferably juxtacardiac, extracardiac or intracavitary electrodes
- the extrasystoles when STIO is disturbed by untimely occurrences of extrasystoles apparently caused by themselves, their suppression is favored by an instantaneous electrical response capable of occupying as soon as possible the still non-refractory areas of the myocardium.
- the intra-cardiac detection only "sees" the extrasystole coming with a delay corresponding to its speed of propagation from its birth until the arrival under the detection electrode which takes place with a speed intra-myocardial of the order of 1 m / second.
- an electrode more external to the heart "sees" the myocardial depolarization propagating with a speed close to that of light. It is therefore necessary to detect extrasystoles, and in particular those considered by programming as dangerous, using juxta- or extracardiac electrodes; as soon as such a detection, confirmed as critical, appears, a burst of stimulation should be caused at one or more or preferably all of the stimulating electrodes. If you have several electrodes stimulants, it is necessary to simultaneously stimulate from them so as to cause fused QRS complexes which block the non-refractory myocardial spaces thus preventing the propagation of new extrasystoles. This system should preferably act within a single mechanical heart cycle.
- the means of the device are sensitive to the acquisition of this extrasystole in order to decrease or even suppress, preferably temporarily, the electrical diastolic phases (D) .
- D the electrical diastolic phases
- the device according to the invention passes from the state of paired stimulation to the state of coupled stimulation.
- Such a device is particularly effective in controlling incipient arrhythmias caused by stimulation or of origin close to the zone or zones in which the stimulation pulses or bursts are addressed.
- the device can be arranged, in case of arrhythmia, to, on the contrary, decrease the intensity of the burst pulses, the device then monitoring whether the arrhythmia continues. In this case, the intensity of the stimulation may be increased.
- the device according to the invention can be used effectively in the event of atrial fibrillation, causing a ventricular arrhythmia.
- the device according to the invention is arranged to acquire the cardiac mechanogram, preferably until the occurrence of a cycle long enough to obtain a good myocardial contraction compared to the current instantaneous rhythm, defined, for example, by a threshold preprogrammed and the stimulation means then send a pulse or a burst of stimulation at an instant situated inside the systolic plateau of the curve of the mechanogram, that is to say of the relatively flat top of the curve of the mechanogram.
- the electrical refractory period ZRE can be located as a percentage of the duration of the previous cycle, the pulse being launched in said plateau of the hemodynamic curve preferably a little before the end of this mechanical refractory zone maximum contracted, for example 30 to 40 ms before the end of this ZRMM zone, which end of zone can be detected by an intramyocardial local pressure microsensor at the location close to the active electrode for sending a burst of pulses spaced 15 ms apart, after which the device immediately stimulates, preferably in a multipolar fashion, after the end of the electrical refractory zone which has just been prolonged, thus canceling the electrical diastole.
- this can be carried out on electrodes located near the area having seen the arrhythmia using electrodes arranged as described above.
- the device can first stimulate the atrium, by an in-ear electrode, then, if necessary, the ventricle by an intraventricular electrode, according to a sequence well known in pacemakers. DDD type. It is thus possible, by STIO stimulation at the atrial level, to regenerate or improve the atrial myocardial tissue.
- the stimulation frequency can be progressively decreased by monitoring the premature contractions of atrial origin.
- the device according to the invention can be integrated into an automatic defibrillator (ICD), for example an implanted defibrillator, and be implemented, in particular after a defibrillation shock, or even as a preventive measure for serious arrhythmias.
- ICD automatic defibrillator
- the implanted defibrillators currently include anti-tachycardia means, of the anti-arrhythmic type according to US Patent 3,857,399
- Zacouto and the device according to the invention can, for example, be actuated when the antitachycardia device fails to rapidly reduce a tachycardia.
- the software controlling the device according to the invention is programmed to automatically find the narrow effective zone ZRMM in each cycle concerned, and possibly reduce then the various parameters of the bursts of pulses, in particular their number, until reaching, if possible, a single perfectly targeted pulse.
- the programming which permanently detects the mechanical parameters, preferably with their metabolic consumption (oxygen or equivalent) will have to reverse, by in the event of sufficient or increasing instability, the process of reducing bursts in order to find without delay with bursts the location of the new useful narrow zone of the cycle.
- a quick method to find the ZRMM area is to detect, inside a burst, the effective pulse that produces a propagated depolarization and to progressively reduce its distance from the pulse that precedes it until '' it picks up and no longer causes visible electrogenesis on the electrocardiogram, which will then be caused by the next burst of the burst.
- This automatic search very harmless for the patient, should be repeated periodically, so as not to lose the exact location of the ZRMM during its variations.
- the automatic measurement of this phenomenon can be done by slightly decreasing the intensity of the pulse or pulses which precede the stimulating pulse in a burst and by gradually decreasing the intensity, the voltage or the width of the stimulating pulse until its functional dropout, the next burst of salvo keeping a stimulating intensity; we can then also gradually decrease the intensity of this pulse to measure the change in its excitability threshold and, by gradually shifting it over time, we can thus measure the duration and intensity of this facilitating effect.
- the device may include means for precise measurement of the volume of the heart or of a part of the heart by electrical impedance, or even by localized ultrasound, for example by including an ultrasound probe.
- the subject of the invention is therefore a device for stimulating and / or strengthening the heart muscle and / or myocardial cells allowing a significant increase in the hemodynamic performance of the heart and / or the treatment of tachycardias, tachyarrhythmias or atrial fibrillations, comprising: means of precise acquisition of the cardiac hemodynamics (5, 6) and comprising a means of instantaneous detection of the maximum myocardial refractory zone ZRMM at a precise location of the myocardium, and means for addressing at least one stimulation pulse and, preferably, a burst of stimulation pulses from the local region in which the occurrence of the ZRMM zone is detected.
- It preferably includes means for automatically acquiring (1, 2, 3) the heart rate and optionally its origin, making it possible in particular to know the interval between at least the last two R waves (provoked or spontaneous) of the cycle cardiac unit which has just ended, and means (4) making it possible to continuously determine in real time the duration of the electrical refractory period (ERZ) which follows the last wave (R) of a cardiac cycle, said device being arranged for detecting whether an electrical depolarization signal has indeed been produced by said stimulation in said zone ZRMM.
- ERP electrical refractory period
- the pulse or at least one pulse of a stimulation burst falls into said zone (ZRMM), substantially at the location of the myocardium where the occurrence of said zone (ZRMM) is detected.
- the device may include implanted intracavitary pressure measurement means capable of detecting a zone of maximum pressure in the plateau of the cardiac mechanogram and to which said means for sending a pulse or a burst of stimulation are sensitive.
- implanted intracavitary pressure measurement means capable of detecting a zone of maximum pressure in the plateau of the cardiac mechanogram and to which said means for sending a pulse or a burst of stimulation are sensitive.
- it includes at least one intramyocardial pressure detection sensor.
- Said intra myocardial pressure sensor is located in the intra-atrial septum and / or in a free or intra-ventricular heart wall.
- the STIO will be programmed to stop instantly with alarm emission and analysis of the responsible cardiac parameters, and if necessary defibrillation or antitachycardia stimulation or automatic injection of drugs.
- SIMA Simulator-analyzer
- the invention of STIO by adapting without delay to these various variations of spontaneous functional escapements of the heart, ensures a continuity of its optimal inotropic effect.
- the analysis by theoretical simulation adapted to each patient and its difference compared to the real plot of the cardiac and vascular parameters in real and deferred time makes it possible to continuously show the functional reactivity of the myocardium towards its stimulation by the inotropic orthorythmic pacemaker.
- This STIO stimulation makes it possible to instantly view and enlarge at will the differences between the desired tracks and the actual tracks as well as their variations, which in turn makes it possible to readjust, if necessary, instantly and automatically the parameters of the electrical stimulation. It is thus possible to hatch, color differently and continuously quantify automatically the differences in subtraction of these plots.
- the device comprises: - means for acquiring information relating to the electrocardiogram of a patient, including the heart rate, - means for acquiring information relating to the hemodynamic performance of the patient; analysis means sensitive to said acquisition means to simulate the effect of paired or coupled inotropic stimulation, adapted to the patient's heart.
- said acquisition and comparison means allow the acquisition and comparison of the information cycle by cycle.
- the parameters making it possible to determine the state of the heart in a patient and his reactivity one will retain his electrocardiogram in the spontaneous state or else under the assistance of a pacemaker, for example an orthorhythmic pacemaker.
- a pacemaker for example an orthorhythmic pacemaker.
- the various parameters and means making it possible to acquire them, and in particular for cardiac efficiency, including flow, volume and pressure, oxygen consumption and the like, have been defined previously and are also described in the documents incorporated by reference.
- said parameters comprise at least one of the following parameters relating to the contraction: slope (dp / dt) of the phases of rise and / or fall of the intracavitary and / or intramyocardial pressure; - duration of the systolic pressure "plateau", corresponding to the systolic ejection; - duration of systole (heart contraction); - duration of the diastole (filling phase, including initial motor phase, fast and slow); - relationship between the durations of diastole and systole; - quality of the diastole, in particular filling depression; - electromechanical coupling (duration separating the start of a QRS complex from the start of the mechanical systole it causes).
- the device comprises means allowing a comparison of the information relating to the electrocardiogram and to the hemodynamic performance of a simulation of paired or coupled inotropic stimulation, with corresponding information acquired during an identical or similar subsequent real inotropic stimulation.
- it includes means for acquiring or calculating a threshold level of values of information of the simulated hemodynamic performance adapted to the patient, and in case of exceeding the threshold, provoking a real stimulation, paired or coupled inotropic identical or similar.
- Said means for acquiring information relating to the patient's electrocardiogram and to the patient's hemodynamic performance are arranged to acquire this information at different rates.
- the device is arranged to temporarily impose on the heart of the patient rhythms varying in stages or gradually, during which said information relating to the electrocardiogram and said information relating to the corresponding hemodynamic performance is acquired.
- said means sensitive to said acquisition means are arranged to simulate the effects of several inotropic paired or coupled stimulations at different heart rhythms. It is preferred to carry out said comparison during a limited number of cycles of the real inotropic stimulation and, in the event of finding the absence of a satisfactory level of hemodynamic performance, to terminate the stimulation in progress. Said number of cycles can be, for example, of the order of ten or less, in particular 1, 2 or 3 cycles.
- the device is preferably arranged so that, in the event of a sufficient increase in initial hemodynamic performance, continuing the inotropic stimulation and detecting and memorizing whether the increase in initial hemodynamic performance is maintained and / or progressively increases during a greater number of cycles.
- Said greater number of cycles is preferably at least one hundred cycles.
- Said means of analysis can be arranged to include the drug inotropic effects liable to interfere with the effect of the electrical inotropic stimulation.
- the device may include means for visually and / or quantitatively underlining by calculation, the differences between the curves of the simulation and the corresponding real stimulation.
- all this information relating to the electrocardiogram, to the heart rate and to the hemodynamic or physiological characteristics is obtained and stored in the device according to the invention, whatever the spontaneous or stimulated heart rate of the patient.
- the simulation is refined by the analysis which is made by comparing the variations of the parameters, and in particular of the parameters listed above, with the different rhythms.
- These changes in cardiac rhythm or reactivity can also be acquired by subjecting the patient to the action of appropriate drugs which act, for example, on the rhythm and / or contraction of the heart, for example dopamine.
- the electromechanical coupling and the way in which it can vary when the rhythm varies will give a good indication of the mechanical reactivity of the heart after stimulation.
- the slope of the pressure rise (dp / dt) will give an indication of the capacity of the heart muscle to generate a pressure increase while the slope of the pressure decrease could be indicative of the compliance or the elasticity of the muscle. heart, and therefore its filling capacity during mechanical diastole, depending on the rhythm.
- the device according to the invention is programmed to use the information thus acquired and to propose, at least for the spontaneous rhythm or the basic rhythm of the patient, and preferably for other rhythms, an electrocardiogram and a mechanogram simulating a result of operation under paired or coupled stimulation according to the invention.
- a simulated mechanogram will thus make it possible to obtain, in particular, the simulated cardiac output, and one can then compare this simulated output with the measured output of the patient in spontaneous rhythm or in basic simulated rhythm if necessary, and estimate if the setting implementing inotropic stimulation according to the invention would make it possible to obtain a significant increase, preferably at least 20% of the flow rate leading to a significant improvement in the patient with heart failure.
- Performing simulations at different rhythms makes it possible to estimate the cardiac rates corresponding respectively to these rhythms and, if necessary, to select a particular rhythm, for example accelerated, for a patient with heart failure having a relatively low spontaneous rhythm, or decreased , for example for a patient with a high spontaneous rhythm, which one can hope to decrease by the inotropic stimulation according to the invention.
- the following steps of the method according to the invention then consist in applying to the patient the inotropic stimulation chosen thanks to the simulation step, in instantly acquiring the results of this stimulation, and in comparing these results with the theoretical results of the simulation.
- the device is preferably programmed to immediately check the changes in hemodynamic performance after a very small number of cardiac cycles, for example during 1, 2 or 3 mechanical cycles, or during one or a few tens of cycles. If no significant improvement appears and is not maintained, for example after three cycles, the device stops the inotropic stimulation, or, according to the programming carried out, tries an inotropic stimulation under different conditions, for example at a different rhythm.
- the inotropic stimulation according to the invention is continued for at least one hundred or a few hundred cycles and the device checks if the increase in initial hemodynamic performance occurring at the very beginning of the inotropic stimulation, not only continues but gradually increases further during this greater number of cycles and will be memorized.
- the comparison between the simulated increase in hemodynamic performance and the actual increase or change in hemodynamic performance can be obtained, for example, by superimposing the simulated and actual hemodynamic curves and measuring the differences, i.e. at least the difference in throughput, and preferably differences in other parameters, including some or all of the parameters listed above.
- a threshold for example of 10 or 20% below the value of the simulated flow
- the increase in hemodynamic performance exceeds that simulated, by a value for example of at least 10 or 20%
- controlling the inotropic stimulation for example by not sending the pulses or bursts of stimulation paired or coupled only for certain cardiac cycles and not at each cycle where one can also use the oxygen consumption indexes or other indexes as defined in the previous documents incorporated by reference, in order to verify that the The increase in hemodynamic performance does not come at the expense of the availability of oxygen for the patient.
- the electrical and mechanical results of the inotropic stimulation according to the invention will be recorded and processed with those previously acquired to perform the simulation, in order to further specify the particular characteristics of the patient's heart such as defined, for example, by the various parameters mentioned above, which will then make it possible to obtain electrocardiograms and / or refined electromechanical simulation curves.
- STIO when STIO is applied to patients suffering from severe or acute heart failure, it is observed that STIO may prove to be impossible to start or that it will drop during operation. In order to anticipate and oppose these serious incidents, it is necessary to analyze with precision the cause of these non-functioning of the STIO.
- the durations and temporal overlaps of these ZREs and ZRMMs should be precisely measured at substantially the same location in the heart, and if necessary continuously; this function can be performed by the simulator-analyzer (SIMA).
- SIMA When SIMA records a critical shrinking of the ZCE, it can automatically, without delay, properly match the pulses of the bursts so as to try to have at least one pulse regularly targeted within the ZCE.
- the device comprises: - means for continuously measuring, in a location of the heart, the electrical refractory zone ZRE, - means disposed substantially in the region of the heart for precisely measuring the zones of maximum myocardial contraction ZRMM, - the device being arranged to acquire, from said means, the temporal superposition, in the same cycle, of said zones ZRE and ZRMM and to determine the zone not common and posterior to the zone ZRE, called critical zone ZCE.
- the electrical stimulation means are arranged to immediately address at least one stimulation pulse in said region of the heart, during said zone ZCE.
- said means verifying the temporal superposition are sensitive to a shift between the zones ZRE and ZRMM to send a stimulation pulse or a burst providing at least one pulse inside the zone ZCE.
- said sensitive means make it possible to reduce the time interval between two pulses of a burst to increase the probability of having a pulse during said zone ZCE.
- the duration between two pulses of a burst cannot be reduced to less than a value of the order of 10 ms.
- the device stops the coupled or paired stimulation.
- the device memorizes the occurrences and the temporal durations of the zones ZCE during a plurality of cycles and one analyzes their evolution to predict a possible tendency to the deletion of said zone ZCE and, in this case, to implement a processing, in particular by infusion of drugs or modification of the rhythm of the STIO in order to act on the duration of the zones ZRE or ZRMM or their overlap.
- the means implemented by the device according to the invention are, unless they are otherwise described, means which, in their individuality, are conventional in the art, and described, for example, in the various documents incorporated by reference. .
- the acquisition means combine electrodes, known physical or biochemical sensors with signal shaping means and computer processing means, including microprocessors and memories, with software that a person skilled in the art knows. or can produce routinely, from the moment it reads the described operation of the invention.
- the invention also relates to methods of treatment or prevention of cardiac affections comprising the successions of the steps described above, these methods implementing a device as described in the present invention.
- the invention in a first embodiment, relates to a method of electrical stimulation of the heart, in particular for treating or preventing cardiac insufficiencies, and in particular left ventricular insufficiency, or tachycardia, arrhythmia or still to significantly increase a hemodynamic performance of the heart, said method comprising the following steps: - implanting a stimulation device as described according to the present invention; - automatically acquire information on the heart rate, preferably by acquisition of the electrocardiogram, preferably with accelerated progress; - determine, preferably at each cycle, preferably in real time, the duration of the electrical refractory period (ZRE) following the last R wave of the current cycle or of another near previous cycle; - and, in the following cycle, send substantially without delay before the end of said refractory period (ZRE) determined at least one stimulation pulse, and preferably a burst of stimulation pulse, to cause a significant lengthening of the refractory period ( RZ) without causing any mechanical stress.
- a stimulation device as described according to the present
- a method according to the invention for the stimulation of the heart muscle, in particular for one of the aforementioned conditions, comprises the following steps: - automatically acquiring information on the heart rate, preferably, by acquisition of the electrocardiogram; - determine, preferably, at each cycle, preferably in real time, the duration of the electrical refractory period (ZRE), which follows the last R wave of the current cycle or of another cycle previously close; - address, in the next cycle, substantially without delay at the end of said refractory period (ZRE) determined at least one impulse, preferably a burst of stimulation; - automatically acquire information on the cardiac hemodynamics, preferably the pressure / volume curve of the cardiac contraction; - determine the strengthening of said hemodynamics; - in the event of zero or too weak reinforcement, modify the moment of sending and / or the parameters of said pulse or burst until a higher degree of hemodynamic performance is obtained.
- ZRE electrical refractory period
- a ZCE zone is determined in said ZRMM zone after the electric refractory zone ZCE, and if said ZCE zone is existing, at least one stimulation pulse is addressed in said ZCE zone.
- the heart is allowed to generate the spontaneous electrical systole R which causes contractions of the heart muscle.
- a stimulation pulse is regularly sent to the heart intended to cause an electrosystole stimulated R causing myocardial contraction and we send the coupling pulse or the stimulation burst according to the invention substantially without delay at the end of the refractory period, the heart then being stimulated at an electrical rate, said stimulation pulse or burst being then said to be “coupled” to the dazzlingsystole.
- the determination of the duration of the electrical refractory period (ZRE) can be obtained by the steps as described with regard to the operation of the device according to the invention, for example by calculation and / or by scanning. , and / or measure.
- the burst of pulses is addressed a little before the estimated end of the refractory period (ZRE), the duration of the burst and the number of pulses being such that electrical stimulation will occur very quickly after the end of said refractory period (ZRE).
- burst pulses which triggered a wave (R ') which prolongs the refractory duration (ZRE) we detect that of the burst pulses which triggered a wave (R ') which prolongs the refractory duration (ZRE) and, if necessary, we modify in the following cycle, at minus one characteristic of the salvo.
- these characteristics are, in particular, the moment when the burst begins, its duration, the number of pulses, the interval between pulses, and the intensity of the burst pulses.
- anti-tachycardia stimulation means and means sensitive to the extrasystoles are also used to stop the programmed stimulation automatically in the event of excessive hemodynamic instability or severe electrical arrhythmia meeting pre-selected criteria.
- Said means act on parameters such as: a programmed ventricular rhythm and / or an automatic adjustment of the beginning or the end or of the duration of the burst or the number or the characteristics, in particular width, intensity, polarity, density, interval of the pulses in the burst, or a localization of the sending of the burst on one or between different stimulation electrodes.
- metabolic parameters are acquired, in particular consumption of oxygen and / or its equivalents, such as the measurement of the densities of electrons of myocardial cell membrane, or increase in ketone bodies, lactic acid, etc.
- a stimulation pulse or burst is addressed within the zone (ZRMM) situated inside the plateau of the contraction curve of the mechanogram and during which the myocardial contraction is substantially maximum.
- the pulse or at least one pulse of a stimulation burst falls into said zone ZRMM.
- said zone (ZRMM) is acquired automatically.
- the intracavitary pressure is measured by a sensor and a maximum pressure zone is detected and chosen in the systolic plateau of the cardiac mechanogram in which a pulse or a burst is sent.
- the local intramyocardial pressure is measured near a detection and stimulation electrode.
- myocardial pressure is detected in the intra-atrial and / or intraventricular septum.
- the variation in volume of the heart, or of a part of the heart is measured by detecting the zone where said volume has reached and maintains its minimum value.
- the invention also relates to a method, in which: - information relating to the electrocardiogram of a patient is acquired, including the heart rate, - information relating to the hemodynamic performance of the patient is acquired; - and we use this information to simulate the effect of prolonged inotropic paired or coupled stimulation. Said acquired information relating to the patient's hemodynamic performance is compared to the simulated effect on said performance of inotropic paired stimulation. Preferably, the information is acquired and compared cycle by cycle.
- At least one of the following parameters relating to the heart contraction is measured: - slope (dp / dt) of the phases of rise and / or fall of the intracavitary or intramyocardial pressure; - duration of the systolic pressure "plateau", corresponding to the systolic ejection; - duration of systole (heart contraction); - duration of the diastole (filling phase); - relationship between the durations of diastole and systole; - quality of the diastole, in particular filling depression or speed and amplitude of the fast and slow phases; - electromechanical coupling (duration separating the start of a QRS complex from the start of the mechanical systole it causes), - lag between the local intramyocardial contraction curve and the overall ventricular intracavitary contraction curve.
- a threshold level of values of information from the simulated hemodynamic performance of the patient is acquired or calculated, and if the threshold is exceeded, an identical or similar inotropic, paired or coupled stimulation is triggered.
- the information relating to the patient's electrocardiogram and, to the patient's performance and hemodynamics is acquired at different rates, in particular increasing or decreasing in stages or gradually.
- means are used which are sensitive to said acquisition means arranged to simulate the effects of several inotropic paired or coupled stimulations at different cardiac rhythms.
- said comparison is carried out during a limited number of cycles of real inotropic stimulation and, in the event of the finding of the absence of a satisfactory level of hemodynamic performance, the inotropic stimulation in progress is terminated.
- inotropic stimulation is preferably continued and it is detected whether the increase in initial hemodynamic performance is maintained and / or progressively increases over a greater number of cycles.
- cardiovascular drugs previously administered or being administered may be used in the analysis.
- the differences between the simulation and stimulation curves are emphasized visually and / or quantitatively, in particular by superimposing the curves.
- the cardiac mechanogram is acquired, in particular until the appearance of a cycle long enough to obtain a good myocardial contraction, and a pulse or a burst of stimulation is then sent at an instant situated inside the plateau.
- ZRMM curve of the mechanogram
- ZRE electrical refractory zone
- the subject of the invention is also a method of treating acute or severe heart failure in which: - the heart rate is automatically acquired, and in particular the interval between at least the last two R waves (provoked or spontaneous) of a cardiac cycle which has just ended, - the duration of the electrical refractory period (ERZ) which follows the last R wave of said cycle is preferably determined continuously, - the end of the period is addressed substantially without delay refractory (ZRE), at least one stimulation pulse and, preferably, a burst of stimulation pulses, the duration of the burst then being such that, taking into account the repetition interval of the pulses in the burst, a pulse of stimulation of the salvo is addressed to the heart substantially without delay after the end of the refractory period, and - these stages are repeated over a series of at least three contra If there is an initial improvement in cardiac performance, - and, if there is no improvement, the process is automatically stopped.
- the mechanical performance of the total heart is advantageously compared, in particular its blood flow and / or the variation in ventricular volume, on the one hand, before the implementation of the steps of the method and, on the other hand, after the implementation of the steps of the process, and if the increase in the performance of the heart is greater than 15%, the process steps are implemented again;
- the subject of the invention is also a method of cardiac resuscitation in a patient suffering from a severe or critical cardiac failure in which: - the heart rate is automatically acquired, and in particular the interval between at least the last two R waves (caused or spontaneous) of a cardiac cycle which has just ended, - the duration of the electrical refractory period (ERZ) which follows the last R wave of said cycle is preferably determined continuously, - it is addressed substantially without delay, to at the end of the refractory period (ZRE), at least one stimulation pulse and, preferably, a burst of stimulation pulses, the duration of the burst being such that, taking into account the repetition interval of the pulses in the
- Another subject of the invention is methods of treatment or prevention of cardiac arrhythmias, in particular spontaneous, implementing the steps listed above for the application of the device opposing arrhythmias. It also relates to methods of treatment or prevention of cardiac arrhythmias caused by, or associated with the implementation of a device according to the invention, said method implementing the corresponding steps listed above.
- the subject of the invention is also a method of physiological and / or anatomical and in particular cellular regeneration of the myocardium in the case of an insufficient cardiac muscle, this method preferably comprising the steps described above.
- Such a method according to the invention comprises the following steps: - implanting in the heart, for example in a right or left atrium and / or a right or left ventricle, regeneration cells, in the subendocardial or intramyocardial position, preferably in several groups of cellular clusters or in the cellular web, - And provide stimulation according to the invention, preferably paired stimulation.
- Such another method according to the invention comprises the following stages: - obtaining and cultivating, in vitro, regeneration cells, preferably in the form of small clusters, - putting these cells in electrical conduction contact with one another and with a device for electrical stimulation, - periodically send electrical impulses to said cells, - detect the responses of electrical or potential depolarizations and repolarizations of the membrane of cultured cells, said cells being intended to be implanted in the heart, preferably in several groups or layers of cells, in the subendocardial or intramyocardial position, once their electrical detection by intracellular micro-electrodes has shown the capacity of the cells for rhythmic electromechanical activity adapted to the recipient's myocardium.
- the stimulation may be simple electrical stimulation at a rate, preferably, on the order of a normal heart rate. It can, preferably, after an initial period, be sent in paired or coupled form, once the clusters or groups of cells in culture are synchronized and manifest an acceptable electrical refractory period relative to the myocardium of the recipient.
- the cultured cells can be of any type, for example muscular, myocardial, embryonic or stem or totipotent or multipotent cells.
- These cells may also have been obtained by a process in which a functional nucleus or part of a totipotent or multipotent or embryonic stem cell, or a nucleus or part of a foreign nucleus or chromosome or genes, is transferred into a functional oocyte nuclear material at an unfinished stage of mitosis to transfer it to a cell, preferably of origin or autologous, totally or relatively differentiated.
- the regeneration can also relate to vascular parts, for example coronary, implementing such means, with suitable stimulation or coronary functioning.
- these cells can be genetically modified to overexpress the telomerase or protein Sir2, in particular by transfection with a viral or retroviral vector, or other vector, the telomerase gene or protein Sir2 reverse transcriptase (hTERT), using for example the technique described by Steven Goldman, Nature Biotech., February 16, 2004.
- STIO according to l he invention is also applicable to the regeneration, at least partially, of the heart muscle, in particular in chronic or acute heart failure patients by implementation of STIO, even in the absence of supply of cells, continuously or by periods, for a long period, for example from a few weeks to several months or more.
- the subject of the invention is also a process for the preparation of living cells, in particular plant, animal and human cells, capable of being reimplanted for prophylactic or therapeutic purposes, in which transport is carried out in an oocyte, preferably unfertilized or recently fertilized , of homologous or heterologous mammal, preferably completely or partially emptied of its nucleus beforehand, of a nucleus of a dedifferentiated cell, so as to induce a stage of mitosis of said transferred nucleus, in that this nucleus is removed during mitosis and before the end of it, then this partially dedifferentiated nucleus is introduced into mitosis at this stage in a cell, preferably after having removed part or all of its nucleus (s), so as to induce and complete its nuclear differentiation division and form a cell strain or tissue at a stage of differentiation less advanced than that of said differentiated cell.
- an oocyte preferably unfertilized or recently fertilized
- homologous or heterologous mammal preferably
- the nucleus transferred to the metaphase, anaphase, prophase or telophase stage of the first mitosis can be extracted.
- the partially dedifferentiated cells obtained, preferably after or during their cell multiplication culture after the formation of a confluent assembly can be subjected to periodic electrical stimulation of the cardiac stimulation type, in particular according to the stimulation method of the invention.
- said cells are subjected to coupled or paired electrical stimulation in which this impulse without any contractile effect is sent shortly after the end of the electrical refractory period of the cells in culture.
- said cells are subjected to electrical stimulation according to cycles comprising a first stimulation pulse and, towards the end of the refractory period, a train of pulses, so that at least one of the train's pulses falls little after the end of the electrical refractory period of the cells and during their mechanical refractory zone of maximum contraction.
- the cells obtained by this process can be implanted in the atrial myocardium, in particular in the case of a patient suffering from atrial fibrillation.
- the invention also relates to an arterial segment or stent, in particular for coronary, aortic, carotid, renal or femoral purposes, comprising a structure coated or colonized by cells obtained by the methods according to the invention, preferably consisting of cells alive, autocontractile and elastic, in particular autologous, cultivated according to the process.
- This arterial segment or stent can be shaped like an arterial stent arranged to be introduced into an arterial lumen.
- it comprises means ensuring electrical stimulation of the arterial type, coordinated with the ventricular diastole, of said segment cells, for example at least one stimulation and / or detection electrode.
- the stimulation and / or detection electrode has preferably been introduced into the cell culture to be surrounded by said living cells.
- the segment or stent may comprise a sensor, in particular for measuring oxygen saturation and / or metabolic parameters, and an electrocardiographic detection or stimulation sensor. It can have a plurality of electrodes arranged to obtain variations in the local electrical impedance. Preferably, it has a structure, in particular in expandable meshes supporting different cellular layers, such as endoartheres, myoarteries and periarteries, said structure allowing spontaneous growth with progressive widening of its lumen and creation of a vascularization nourishing in particular the myoarterial part. .
- the structure is produced, for example, from at least one of the following materials: PLGA, collagen, globin, for example by knitting.
- the subject of the invention is a biological cardiac pacemaker comprising partially dedifferentiated cardiac autorythmic cells or tissues according to one of claims 110 to 122?, Preferably autologous, homologous, originating from the recipient organism, and intended for be implanted in the heart or a failing region of the heart.
- FIG. 1 schematically represents an electrocardiogram associated with a myocardial mechanogram corresponding to the operation of a device according to the invention
- - Figure 2 represents a view of a real example
- - figure 3 represents the acquisitions of different parameters in the functioning of the invention
- - figure 4 represents a schematic view of a cell implantation device
- - figure 5 represents a view schematic of block diagram of a device according to the invention
- - Figure 6 shows a schematic view of a device according to Figure 5, further having additional means.
- FIG. 7 shows schematically the electro-cardiogram and mechanogram of a STIO according to the invention for a slow spontaneous rhythm
- - Figure 8 shows schematically the electro-cardiogram and mechanogram of a bradycardizing STIO
- - Figure 9 shows schematically the different electrical and mechanical zones distinguished in the invention
- - Figure 10 shows schematically the electro-cardiograms and mechanograms used in the simulation according to the invention
- - Figure 11 shows a control and display panel of a device according to the invention.
- Figure 1 shows an example of the operating principle of a device according to the invention.
- the upper line shows the ECG
- the middle line shows the Y couplings of the orthorythmic bursts with respect to the R waves of the basal rhythm, that is to say as a percentage of the duration of the previous cycle Z
- the lower line shows the myocardial mechanical activity.
- the solid R waves represent the spontaneous or stimulated depolarizations and the dotted RV waves the basal R waves inhibited by the artificial extension (RZ) of the refractory zones induced by the bursts of the electrical impulses.
- the bursts of five pulses of the stimulator according to the invention are clearly visible on the ECG and the first pulse of each burst, which causes depolarization, allows the measurement of each functional refractory zone (ZRE or RZ) in each cycle.
- ZRE functional refractory zone
- ZNRM mechanical non-refractory zone
- the ZRMM interval corresponds to the period of the maximum contracted systolic refractory zone still active during which propagated electrical stimulation causes practically no effect or myocardial energy expenditure because this muscle, being in maximum contraction just before its active relaxation , is incapable of any other costly biological action.
- the ZRMM is followed by the mechanical non-refractory zone (ZNRM).
- ZNRM mechanical non-refractory zone
- the different functional zones and in particular the ZRE and ZRMM can vary from one cycle to another, for example between 15 and 80 ms; this in part already favored by cardioactive drugs, vegetative tone and by variations in pre and post-charges, trans-membrane fluxes and other intracellular metabolisms.
- classic paired stimulation which uses only one electrical pulse to prolong the ERZ, with a constant coupling interval in ms, cannot achieve clinical safety STIO because the only stimulus with fixed coupling will sometimes fall before, during or after the moving critical interval, which remains invisible on a normal ECG.
- this process can make it possible to instantly control certain implanted drug pumps (Zacouto, US patent 5,305,745) and if one has several electrodes, preferably quite distant, of stimulation in the heart (for example stimulation of ventricular resynchronization) a Sufficient and sudden difference between these refractory zones and the excitability thresholds can indicate a coronary thrombosis or local myocardial lesion.
- the diagnostic functions of STIO according to the invention can alone justify its application, for example, in the case of the use of drugs influencing cardiac functioning if necessary by cutting off the stimulation functions.
- the clinical use of STIO should be distinguished according to whether it is applied to tachycardia or myocardial insufficiency.
- the STIO makes it possible, as soon as the cardiac stimulation electrodes are installed, to quickly reduce its rhythm by approximately two with a considerable and immediate increase in cardiac output, this which is due on the one hand to the great extension of the diastole and on the other hand to the RPE which is added to it.
- ventricular tachycardias TV
- STIO In the case of acute or chronic heart failure not caused by rapid ectopic tachycardias, which are often in moderate sinus tachycardia, STIO immediately causes a decrease in rhythm (e.g. from 100 p.m. to 60 p.m. and a significant increase and lasting cardiac and coronary output as well as an immediate and persistent drop in pulmonary arterial pressures.
- a decrease in rhythm e.g. from 100 p.m. to 60 p.m. and a significant increase and lasting cardiac and coronary output as well as an immediate and persistent drop in pulmonary arterial pressures.
- irreducible or recurrent tachycardias in particular TV
- one can reduce their rhythm by two by using a permanent STIO which can be an alternative to ablation or allow waiting, without danger for the patient, an ablation in excellent hemodynamic conditions, which even the return to the sinus rhythm will not be able to achieve.
- STIO implanted STIO
- the sudden and significant increase in hemodynamics caused by a STIO can be a disadvantage for some patients, in these cases one can program the STIO not to launch its bursts or pulses prolonging the ZRE zones for example, only on a spontaneous R wave or stimulated on three or four instead of one on two or decrease the duration of diastoles by accelerating the basic rhythm.
- Coupled stimulation is stimulation without any spontaneous R wave at a rate totally imposed by the STIO.
- bursts of orthorythmic pulses used by STIO can be done automatically by controlling them in relation to the parameters of the desired hemodynamics and preferably by controlling concomitant metabolic changes such as oxygen consumption.
- Another known advantage of the bursts of orthorythmic pulses used by STIO is that on a burst, for example, of 4 consecutive square pulses of duration of 0.5 ms each at 1.4 volts with an interval of 15 ms between the pulses, if the second pulse causes depolarization, the following pulses will quickly exceed (propagation speed exceeding Km / sec) a possible fibrillation starting locally for less than 15 ms (propagation speed approximately 70 cm / sec) and the surround with a refractory zone; moreover, the first pulse of the burst which falls into ZRE eliminates the propagation of possible depolarizations of some earlier cells invisible on the ECG, but which can sometimes initiate an arrhythmia.
- the STIO immediately improves the coronary flow especially by the intervention of the RPE and by the very elongated diastole as that is known in coronarography as well as by the motor start of the diastole which is increased in proportion to the reinforced shortening of the myocardium caused by intensified contractility, which corresponds to a sharp increase in myocardial visco-elasticity during the motor phases; this viscoelasticity can be measured, for example, by a multi-axis pressure detector implanted in the myocardium, such detectors being known.
- the concomitant drop in pulmonary arterial pressures is probably mainly due to the rise in cardiac output.
- STIO should not result in a significant additional expenditure of oxygen.
- a certain increase in oxygen consumption during STIO also corresponds to an increase in the ratio of cardiac output to flow of oxygen consumed; the sudden rise in coronary flow will most often allow this additional oxygen expenditure to be well tolerated. With equal increased hemodynamics, STIO consumes less oxygen than other heart rhythms.
- the STIO aims to take optimal control of the rhythm and contractility of the heart, on the one hand, by occupying the very first electrical non-refractory zone beginning in a cardiac cycle and, on the other hand, by trying to ensure optimal contractility and desired blood flow per minute; this last claim requires a check in real time geometric and / or volumetric and energetic of at least one cardiac ventricular cavity.
- a POR with STIO implantable or not, it is preferable to provide a device requiring very little energy, for example of the type measuring intra-cardiac electrical impedances.
- the parameter of the course of the volumetric variations is preferably supplemented by that of the concomitant intracavitary and / or intra-myocardial blood pressures in order to reproduce a correct pressure-volume curve, preferably displayable outside the body by conventional telemetry.
- an electronic device can be produced which integrates, for example, the surface of the pressure curves and, if possible, the corresponding volumes or speeds and blood flow rates (for example, by type of measurement of intra-electrical impedances compared to the programmed ventricular rhythm, and which then imposes a rhythm close to the value which has detected the most favorable hemodynamics for a given patient at a given time, after having performed, memorized and compared these values obtained after a certain frequency sweep (Zacouto, US 5,306,293).
- an automatic adjustment of the pulses constituting the orthorythmic stimulation burst with respect to the hemodynamics and / or the oxygen consumption can vary the number of the pulses, their interval which can be non-equidistant, their width, their shape. , their polarity, their intensity and their voltage which can also be uneven as well as the location of their application at the level of the heart.
- This localization of their application may include fixed or variable monopolar, bipolar or multipolar stimulations, with endocavitary, intra-myocardial, epicardial or intra-venous atrial or ventricular electrodes, coronary intra-arterial, intra-stent such as special stents with electrodes ECG and / or stimulation with or without hemodynamic sensors, oxygen saturation and / or CO 2 , pH, blood sugar or other metabolic indicators.
- intra-stent such as special stents with electrodes ECG and / or stimulation with or without hemodynamic sensors, oxygen saturation and / or CO 2 , pH, blood sugar or other metabolic indicators.
- the control of the cardiac rhythm which the STIO gives according to the invention includes the possibility of accelerating and also of slowing down an accelerated heart, this which also distinguishes it from classic cardiac pacemakers.
- the electrical non-refractory phases are not prolonged as much as with a spontaneous bradycardia.
- STIO can automatically switch to coupled ventricular pacing, which removes any spontaneous QRS complex and provides an effective ventricular rhythm which is half the fast paced ventricular rate.
- the ventricular STIO can make it possible to protect the ventricles from the impulses of AF completely for the impulses of AF which fall early in the ventricular cycle (CV) and partially for the impulses occurring later in the CV , if necessary by potentiating with certain drugs slowing the conduction His Jardin, which gives to the ventricles a sufficiently regular rhythm, for example eliminates all the CV lower than 600 ms., partly adjustable and accompanied by an optimal contractility; this can compensate for and overcompensate for the unfavorable effect of AF on myocardias tired by tachyarrhythmias and weak coronary flow rates and possibly potentiate the effect of Digoxin and other cardioactive drugs.
- Atrial STIO maximally increases atrial contraction and strengthens muscle power, opposes dilation, thrombosis, resettlement of certain AF (atrial fibrillation) and improves ventricular and coronary flow rates if the STIO parameters are correct adjusted for activations natural or artificial auricular and ventricular.
- Atrial stimulation can, for example, be performed as a bipolar from electrodes placed on the upper half of the atrial septum, which can help synchronize the atria without hampering the ventricles.
- a co-ordinated double atrial and ventricular STIO maximizes the co-ordinated atrial and ventricular contraction can be very useful, with Hisian blockage or not, to considerably increase cardiac hemodynamics without delay and for a long time.
- Any STIO adapted according to the invention regenerates a genetic functioning with an inotropic effect of the myocardium with modifications of the expression of the development genes, ion channels and contractile functions induced by the imposed mechanical and metabolic constraints imposed; these will lead to its intracellular reshaping of functional recovery, for example in the event of heart failure (dilations) or necrosis (shriveling).
- This etiological therapy for each heart failure can give a rapid genetic involution of its pathological process and genetic modification of physiological and anatomical regeneration caused by the effect of contractility greatly increased to the specific evolutionary possibilities of each patient, automatically adapting to each case.
- certain diseases such as metabolic, tumor, viral, toxic etc. prevent myocardial function from recovering. Maintaining the recovery of cardiac function requires sufficient peripheral muscular activity which should be coordinated with the central myocardial action of STIO.
- STIO For certain necrosis or extensive fibrosis of the myocardium, local autologous grafting of multiplied and differentiated stem cells in vitro or of genetically transformed or reprogrammed cells by mechanical electrical and biochemical training capable of recolonizing the destroyed sites and metabolizing certain scar tissues is envisaged.
- the in vitro multiplication of the cells to be grafted must not always be done in the stationary state, but preferably also, under a controlled alternating mechanical stress adapted to the future functions of the cells and capable of inducing an electrophysiological membrane state compatible with the function of the heart to be served, and preferably controlled by a STIO adapted to the functional capacity of the cells in order to orient them genetically towards their future contractile function, and this, if possible, with autologous serum.
- these cells should be encouraged not to multiply all separately but, for example, to form small functional structures in three dimensions by cultivating them, for example, on a preformed, porous, elastic and biodegradable matrix such as PLGA and PLA (derivatives of poly-lactic acids) to prevent their dissemination after their injection and promote their contractile function in syncytium coordinated with the stimulation of the heart.
- Small preformed dies can have 3D shapes which favor their mutual assembly and with the recipient's myocardium, for example in the form of strips, discs, brackets, crosses, streamers, etc.
- These cells prepared for their contractile function can also be used in the event of AF to form an implantable myocardial tissue in the atria, achievable, for example, through a catheterized venous pathway, under at least echocardiographic control, the probe or probes that can also pierce the ear septum to also seed the left atrium; this sub-endocardial semen of clusters of these myocardial cells implanted either one by one, or as a bridge between several rootings carefully to avoid perforation of the wall as well as a detachable protrusion in the atrial cavity, this can be done by a steerable catheter fitted at its end with a cylinder containing a narrow retractable spout of the pointed and flexible catheter sliding on the endocardium lifting by suction the endocardium and the pricking very slightly at this point by pushing a cylinder of cells to be implanted (CLI) in the small crack obtained using a piston which is full in thrust and which is in recoil joined to the walls of the catheter
- the clusters and bridges of implanted cells will expand and form a contractile mesh network controlled by a STIO or simple stimulation, for example located in the right atrium and the CLIs should, by proximity effect, merge into the syncytium of origin and induce certain parts of their genetic equipment there.
- a cell implantation catheter can be applied to any region of the heart and other organs such as the kidneys, pancreas, liver, etc.
- This principle of implantation of multiplied autologous cells which can be multiplied easily and prepared for a contractile function can also be applied to the construction of a total or partial artificial heart constituted at least partially by autologous cultured cells, preferably from partially dedifferentiated myocardial cells.
- a partial cellular therapeutic cloning is carried out which consists in introducing into a stripped oocyte a total or partial foreign nucleus and in removing this nuclear material at a desired uncompleted stage of its mitosis and implanting it then in a cell preferably autologous, differentiated pitted or not, in which will end the first mitosis leading to partial dedifferentiation.
- a purely nuclear partial cloning consisting in removing the cell nucleus in selected and not completed mitosis from the oocyte before the first complete cell division, at a determined time, by analysis, for example optical, of the evolution of the nucleus.
- telophase if slight dedifferentiation is desired or, during anaphase or telophase, if stronger differentiation is desired. Then, it will be introduced into a living cell membrane preferably emptied of its nucleus, preferably autologous, embryonic or stem cells for example dermal, epithelial, lymphatic, conjunctiva, bone, cartilaginous, blood or muscle. These cells can then be introduced, resulting from incomplete cloning, into a myocardial cell where it can exercise transcription and regenerative genetic expression capable of inducing at least locally and temporarily, in its environment, a partial genetic action and contamination of a desired degree.
- nucleus preferably autologous, embryonic or stem cells for example dermal, epithelial, lymphatic, conjunctiva, bone, cartilaginous, blood or muscle.
- a nucleus already present spontaneously or by known artificial provocation, in uncompleted mitosis or even in completed mitosis, in the form of the first two cells, in order to obtain more easily a partial dedifferentiation.
- it is planned to make an oocyte multiparous by introducing a new nucleus after delicately removing the first nucleus in partial mitosis.
- This multiparity by consecutive intra-oocyte inoculation can have on the nuclear material a differentiation effect different from that obtained during the first introduction of the nucleus or chromosomes or genes of this same oocyte.
- This will preferably be of the same tissue, for example myocardial, preferably partially pitted and cultivable in vitro, vivo or in situ.
- This or these cell (s) will be cultured for multiplication preferably a sufficient time in vivo in embryonic tissues to obtain a partial dedifferentiation.
- the nuclei thus treated can be left either in cells of the embryonic type to constitute a graftable tissue in the organism from which the nucleus originates, or extracted from their host cells to become an inducer of local cellular regeneration in a differentiated tissue, preferably autologous and identical.
- the implantation of the nuclear nucleus or parts can also be done inside a stem cell, preferably of the embryonic or fetal type.
- a stem cell preferably of the embryonic or fetal type.
- Such partially and selectively dedifferentiated cells can then be introduced into myocardial cells, preferably of origin, in survival, preferably more or less pitted beforehand and serve as regenerating myocardial tissue to be implanted, for example, in regions sclerosed by fibrosis, poorly vascularized, or with insufficient contractility of the heart. From a certain degree of dedifferentiation, these cells lose their immunogenic power and can be used to regenerate non-autologous myocardial tissues.
- This function also includes the capacity of these genetically activated cells to act at a distance by secretion, release or induction, in particular by specific biochemical molecules.
- This trans-humoral genetic activation shows, among other things, the ability to mobilize pro-generative cells of local appearance as observed in extensive myocardial infarctions.
- This cell preparation also applicable to other cell types, can create tissues of controlled regeneration making it possible to treat numerous organic and tissue lesions.
- prostate cells which will be totally or partially cloned by trans-rectal needle and by reinjecting them by the same route into the prostate, this inducing cell rejuvenation may, in certain cases, s '' oppose the development of local cancer or slow its spread.
- an autologous, even homologous, regenerated ophthalmic retina may be of great interest in the case of AMD, and severe renal insufficiency may be combated by the implantation of partially dedifferentiated cells obtained, after transfer into and then out of oocytes, nuclei from different nephron cells, and osteoarthritis relieved by the implantation of chondrocytes from partial cloning; the same applies to skin surfaces and in particular to regenerate normal hair, for example by transferring into the oocyte one or more nuclei or parts of nuclei of hair follicle and / or melanocyte cells, for regeneration of the hair and / or its color.
- An important application of the invention consists in strengthening or recreating thymic functions by genetic rejuvenation of homologous or if possible autologous partially dedifferentiated thymic cells in order to actively revive the immunoprotective functions of the body.
- a main application of the invention consists in transplanting these partially dedifferentiated cells and functionally trained in synchronized contraction in the laboratory by implanting them, for example, in layers or grids in contact with the atrial myocardium where they can gradually multiply and / or grow and / or genetically modify the diseased cells of the atrial myocardium, and / or also act by secretory activity and humoral, biochemical, mechanical or physical induction, can be by intervening in a morphogenetic field.
- a myocardial cell is excised under a microscope and the membrane and the cytoplasm are kept alive in culture after having extracted one, several or all of the nuclei.
- This or these extracted nuclei will be introduced individually or in a group into an oocyte or several oocytes, preferably previously enucleated, and we will wait, preferably by observation under a microscope, only for pro-, meta-, ana-, or telephase before taking them. and to reintroduce them into the membrane and the cytoplasm kept alive or livable in culture or else in another syncital myocardial cell, preferably emptied of a part or all of its nuclei.
- biodegradable elastic stakes for example a collagen matrix or an elastic biodegradable textile in vivo, and preferably preferably gradually stimulated by simple or inotropic orthorythmic pacemaker in order to to adapt physiologically to their future insertion, either in the sick or senile myocardium of the patient, or to constitute the auto-contractile walls of a partial or total artificial heart, and implanted subsequently in the patient, in particular also at the ear level for suppress atrial fibrillation, in particular also to form segments of active and contractile coronary arteries usable as coronary stents conductors and physiological propellants, this coronary contractility and additional active and passive distensibility can be caused if necessary by arterial stimulation and electric arterial smooth muscle offset in diastole from the ventricular contraction, or form an almost whole or additional coronary artery, for example, which may come from a dedifferentiation or partial cloning of
- a selected part of a chromosome or an entire chromosome or gene is introduced into a suitable functional oocyte, either alone or accompanied by a part of the nucleus or of the differentiated cell nucleus, preferably autologous to 'origin or not of origin, partial or whole to be treated.
- a suitable functional oocyte either alone or accompanied by a part of the nucleus or of the differentiated cell nucleus, preferably autologous to 'origin or not of origin, partial or whole to be treated.
- These nuclei to be treated can be selectively deprived of the diseased chromosome (s) to be replaced in order to make the nucleus tolerate its genetic chromosomal reconstruction of selective and / or partial dedifferentiation.
- one or a group of genes can be substituted for the part of the chromosomes or for the whole chromosomes to be dedifferentiated without thereby going beyond the scope of the invention.
- the extraction of partially dedifferentiated nuclei or chromosomes could be done, for example, by intra-oocyte injection of a suitable serum under light pressure after having sufficiently mobilized the nuclear material with a micro-rod or pallet or by the vibratory action d or laser.
- a suitable serum under light pressure after having sufficiently mobilized the nuclear material with a micro-rod or pallet or by the vibratory action d or laser.
- these artificial genetic elements do not support any genetic involution of dedifferentiation, their future functionality is uncertain.
- Tissue grafts require for their success the sufficient elimination of the lymphocyte reactions of serious rejections generally of antigen, antibody and humoral type from the recipient organism as observed in pregnant women who tolerate biologically, through their placenta, their fetus. It is appropriate, for example, to genetically and / or plasmatically imitate these tolerance characteristics, in particular lymphocyte and thymus functions. In adult and especially elderly humans, the presence of thymus cells and functions is often too weak or even absent.
- a homologous thymus tissue partially and selectively dedifferentiated and genetically adapted, for example, by selective chromosomal integration of graft chromosomes into cell nuclei of the recipient organism and this either by genetic preparation of blood stem cells of the recipient organism either by preparation in cell culture in vitro or in vivo (such as sub- or intradermal) with or without hyper-expression of their telomerase or protein Sir2 to prolong their life and to cause their induced habituation to antigens and critical antibodies of cells to be grafted by known means of the influence induced at a distance by biochemical and hormonal substances on the expressions of certain genes.
- Such cells genetically adapted to different recipient tissues can be used in particular for the radical cure of atrial fibrillation as well as for retinal regeneration, implantations of pancreatic tissues without protective membrane, regenerating nephrons, intra-cerebral dopaminergic cells against the disease.
- Parkinson's, dermal and epidermal regeneration tissues including hair, prostate tissues or mammary glands for the treatment of corresponding cancers, and in particular regenerative thymus cells and any other functioning or useful cell in particular digestive, nervous, dermal, respiratory, skeletal and cardiovascular tubes and systems.
- Coronary, carotid, renal, etc. arterial lesions can be fatal and ideally require radical treatment for tissue and functional regeneration.
- the invention includes a variant capable of taking autologous or homologous arterial muscle cells and subjecting them to a controlled partial dedifferentiation according to the above-mentioned methods.
- We can then cultivate these arterial cells either in vitro around a preferably elastic stent, dissolvable or not, in the form of a tube and in a serum circulating intra-tube under pulsatile pressure gradually increasing in order to recreate the contractile and elastic relaxation function. cells to reconstitute an arterial tube to the desired diameter.
- partially dedifferentiated arterial endothelial cells will be cultivated in the form of a tube of smaller diameter which will be introduced at the end into the largest tube thus cultivated.
- Such arterial segments partially dedifferentiated and tolerated by the body can then either replace diseased arterial segments or be established in parallel or in addition to a faulty network.
- stents implantable for example by endo-arterial catheterization.
- Current stents are made of an inert and immobile plastic or metallic material and replace a more or less auto-contractile arterial segment but thrombosis, contributing to the desertification of the small coronary arteries and capillaries downstream.
- this "pulsatile physiological stent” will be activated spontaneously, notably by variations in wall and blood pressures. If necessary, the coordinated rhythmic activity of this segment of “physiological stent” can be ensured by an arterial electronic pacemaker adapted to the rhythm of the arterial beat, for example by a detector of the ventricular or intramyocardial intracavitary pressures and / or the ECG and stimulant. in diastole, for example, also in relation to the rhythm of the cardiac pacemaker.
- a sensor of pressures, oxygen saturation and ECG preferably to the cardiac pacemaker or implanted defibrillator
- this reconstituted coronary arterial segment is provided, in living continuity, with arteries, arterioles, capillary and venous networks with their irrigated myocardial tissues; this functional tissue block being previously cultivated and multiplied in vitro or in vivo, preferably from autologous cells, partially dedifferentiated, a sufficient venous mouthing of this tissue being provided towards the ventricular cavity or the coronary venous sinus.
- This highly functional renovated myocardial block can gradually induce recolonization of the capillaries and small coronary arteries of the original myocardium.
- the implantation of a physiological stent by conventional arterial catheterization will work initially by arterial blood supply imbibition, as performed during its cultivation, from the endo-artery.
- a further application of the invention consists in gradually reconstituting in vitro, preferably after partial dedifferentiation of the first cells of the various cardiac tissues and their beginning multiplication, a part of the ventricle, for example in the event of a ventricular aneurysm or necrosis, or '' set of two ventricles, using expandable or fairly flexible or biodegradable stakes and adequate growth factors and respecting the three-dimensional ventricular geometry ensuring vascular connections as can be obtained from an ultrasound three-dimensional cardiac (N.
- the invention can be applied to cell and tissue grafts without serious rejection reactions, by the use of partial and / or selective cloning.
- a selected part of a chromosome or an entire chromosome is introduced into a suitable functional oocyte either in isolation or accompanied by one or two cell nuclei, preferably autologous of the recipient or not of origin, partial or whole to be processed.
- nuclei to be treated can be selectively deprived of the diseased chromosome (s), in particular isolable during a phase of their mitosis which must be replaced by equivalent chromosomes preferably of embryonic or genetically partially dedifferentiated types in order to allow tolerance by the nucleus its genetic chromosomal reconstruction of selective and / or partial dedifferentiation.
- equivalent chromosomes preferably of embryonic or genetically partially dedifferentiated types in order to allow tolerance by the nucleus its genetic chromosomal reconstruction of selective and / or partial dedifferentiation.
- one or a group of genes can be substituted for the part of the chromosomes or for the whole chromosomes to be dedifferentiated without thereby going beyond the scope of the invention.
- a variant of the invention consists in partially co-dedifferentiating in the same or autologous naked oocyte to induce reciprocal immune tolerance between, on the one hand, a cell nucleus of which one or more chromosomes or parts of diseased or senile chromosomes have been destroyed during mitosis and, on the other hand, one or more parts of healthy chromosomes or whole chromosomes, preferably homologous, healthy and younger.
- Such genetically repaired and dedifferentiated cells can also receive an overexpression of their telomerase or protein Sir2.
- the extraction of partially dedifferentiated nuclei or chromosomes could be done, for example, by intra-oocyte injection of a suitable serum under light pressure after having sufficiently mobilized the nuclear material with a micro-rod or palette and / or the application of '' and / or local lasers with vibratory effect.
- An example of starting up the process can be to acquire the hemodynamics and possibly the corresponding oxygen consumption and then to determine the coupling intervals of the paired stimulation, ie relative to the R wave of the ECG in ms, either with respect to the RR interval as a percentage of the duration of the previous cycle, or by an algorithmic combination of the two.
- this STIO is continued and the acquisition of hemodynamics and preferably of myocardial oxygen consumption is continued. If the programmed values are not reached, at least one parameter of the pulse trains is modified and the controls are repeated. If, after the successive programmed modifications of the parameters of the pulse trains, the desired values are not obtained, the STIO is stopped.
- FIG. 5 shows a block diagram of a device implanted according to the invention.
- the technical realization of the various hardware or logic components will not be detailed further, whether it is the detection or stimulation means, energy sources, and logic and memory processing means, which are all now quite classic and well known in implanted pacemakers.
- the device comprises detection and electrical stimulation means 1.
- detection electrodes which can also be used for stimulation, as is often the case.
- Detection means supply signals to the acquisition means of the electrocardiogram 2.
- the device also includes means for detecting hemodynamics 5, such as an intracardiac or intramyocardial pressure sensor and volume sensors by measuring the impedance, and means measuring the kinetic energy of each volume expelled (by example by measuring the slope ⁇ p / ⁇ t of the pressure and / or volume variations, again by sensors implanted with Doppler effect or accelerometers), these means allowing, in means 6, the acquisition of these data the calculation of hemodynamic performance, i.e. the volume of blood ejected and, by relating it to the rhythm, the cardiac output.
- the hemodynamic sensors 5 comprise an intramyocardial pressure sensor situated near an intraventricular detection and stimulation electrode forming part of the means 1.
- the means 6 are sensitive to the amplitude of the pressure detected by the pressure sensor, and check whether this amplitude varies shortly after the pressure build-up, to determine the ZMRR zone.
- the values coming from the means 6 are addressed to comparison means 7 in which one has also memorized either a threshold above which one would like to maintain the hemodynamics, or a hemodynamic optimum which would have been recorded, for example previously, by the device according to the invention.
- These means 7 send the result of their calculation to means 8 which also receive the information relating to the refractory period coming from the means 4 and to the characteristics of the electrocardiogram, in particular the rhythm coming from the means 3.
- the coupling that is to say, the interval which is expected between the last R wave which has just been detected and the sending of the stimulation or of the burst of stimulation pulse
- these means can also, if necessary, modify, depending on the information received, not only the coupling interval if necessary, but also other characteristics, such as the duration of the burst, the number of pulses, the interval between the pulses or the intensity or duration of each of the pulses.
- the means 8 control means 9 for generating a pulse burst.
- the device may also include metabolic sensors 11, for example of local oxygen saturation pressure or its equivalent in concentration of transmembrane or free electrons as measurable by a redox coefficient within a coronary sinus vein and, for example, relating to the right intra-auricular venous blood and left intra-auricular arterial and / or sensors of CO 2 , and / or pH etc.
- a value such as the consumption of O 2 acquired for comparison in means 13 with one or more thresholds programmed or previously memorized.
- the device shown in Figure 6 has the means identical to that described for claim 5, and additional means.
- the means 6 is arranged to be able to identify the zones ZRMM in duration and in geometric position with respect to the zones ZR and ZNR.
- the means of comparison with optimum series already memorized can be arranged to memorize dangerous critical sequences which have already existed or entered by programming and allow an action in the event of detection of a sequence of cycles which is considered critical, for, for example. example act on a defibrillation means or to stop the operation of the device according to the invention and operate it in the manner of a conventional orthorhythmic pacemaker or Wl or DDD.
- the means 3 is also arranged to also acquire the intervals RR 'directly.
- an additional means 15 is arranged to receive information from the means 4, the latter being arranged to acquire information also on arrhythmias, said means 15 thus allowing the detection and selection of arrhythmias, preferably the distinction between arrhythmias. spontaneous and those induced by the device, said means 15 feedback on the means 10, which controls the sending of the pulses.
- STIO allows at rest to immediately follow a basal CC one or more CC with maximum contractility or vice versa and measure their quantitative and geometric difference. For a progressive stress test, however, conventional means must be used. The comparison between the maximum contractility of STIO and that obtained by physical exertion or substances of the dopamine, noradrenaline type, etc., may give new indications on myocardial function.
- An automatic STIO comprises a device making it possible to ensure optimal hemodynamics within adjustable limits, for example of rhythm, pressures: max., Min., Differential, dimensional variations of the contraction, local and general saturations of oxygen (preferably in the coronary sinus and arterial and venous blood), regular continuity of STIO, etc. In order to be able to carry out this developed, it is advisable to have for example (fig.
- a specially programmed display at an oscilloscope with several simultaneous channels and using known signal processing and algorithms which comprises for example, in real time , the following parameters: a) an ECG trace showing 3 to 5 fast-running cycles, b) the marking of spikes for detection and stimulation at the electrodes on a line, c) a trace showing the Intra-cardiac ECG preferably in mono-polar, for example on a tri-polar probe, the stimulation being done in bi-polar, which makes it possible to determine which of the pulses of a salvo actually causes the propagated electrical depolarization thus allowing the automatic measurement of ERZs and their variations at each CC, measurements made possible by the orthorhythmic pacemaker, even in the event of atrial fibrillation (K. Theissen, F.
- the STIO stimulation device can be associated with all categories of implantable DIA automatic pacemakers, and also, in particular, automatic defibrillators, anti-tachycardia, Wl, DDD, DDDR, etc.
- the practitioner or the device according to the invention finds that a patient, suffering from significant cardiac insufficiency, has a spontaneous heart rate that is not accelerated, for example, less than 125 p / min, and for example preferably less than 100 p / min.
- Line 1 in Figure 7 shows the regular rhythm of the R waves (QRS complexes) of this patient, ZRE representing the refractory zone electrical, determined, for example, by one of the means described in the present invention.
- Line 2 represents the mechanogram detected in response.
- the mechanical refractory period ZRM has also been represented, as well as the mechanical diastole D.
- line 3 the electrocardiographic simulation of an isotropic stimulation according to the invention has been represented, in which an immediately coupled burst is sent , at the end of the electrical refractory zone ZRE and we see the extension of the refractory zone which follows the R 'complex caused by the simulated coupled stimulation.
- the computer processing means of the device predicted that the basic rhythm is hardly modified by the simulated inotropic stimulation and the spontaneous complexes R therefore arise as they would in the absence of stimulation.
- the estimated increase in duration and intensity of the mechanogram is represented, an increase which is immediately noted from the second spontaneous R wave, that is to say the first which follows the inotropic stimulation R .
- This also results in a decrease in the mechanical diastolic duration D ′, which is less than D.
- the actual inotropic stimulation of the heart is then carried out as provided on simulation curve 2 of FIG. 7, and one check that an immediate increase in hemodynamic performance is obtained from the first consecutive cycle, as on line 4.
- the device stops inotropic stimulation.
- the stimulation continues, preferably over several tens, or one or more hundreds of cycles.
- the inotropic stimulation is continued.
- the device may possibly decrease the performance, for example by taking into account a CSI cardiac stress index and by comparing CPI performance index and CSI stress index, like this. is described in US Pat. No.
- the inotropic simulation can optionally be performed only for a reduced proportion of cycles. If, on the contrary, the performance observed is much lower than that estimated as necessary and predicted by the simulation, the device can stop the inotropic simulation.
- FIG 8 there is shown a case of heart failure associated with a spontaneous tachycardia rhythm, for example greater than 125 cycles per minute. The last spontaneous cycle R is shown, as well as on line 2, the corresponding hemodynamic performance.
- the device simulates the sending of a stimulation burst towards the end of the refractory period of the last spontaneous signal R, which prolongs the refractory period of the heart, so that the next QRS complex, which would have produced at time R2 due to tachycardia, can no longer occur, which causes the occurrence of a delayed spontaneous R3 complex.
- the burst of coupling stimulation R4 is then continued and we see that by preventing each time the occurrence of the spontaneous tachycardic complex R2, we obtain, ultimately, a lower rhythm, for example divided by 2. Most often, however, we prefer to provide complete electrical management of the heart; the spontaneous R3 complex is then replaced by stimulation at a slightly faster rate.
- This normal stabilized rhythm normally corresponds to an increased simulated hemodynamic performance since the RPE effect (PESP) largely compensates for the decrease in the number of contractions per minute.
- PESP RPE effect
- the inotropic stimulation is actually implemented in accordance with the procedure in line 1 of FIG. 8, and as indicated previously, the response and the amplitude of the response obtained are verified during one, two or three cycles then for a higher number of cycles.
- FIG. 9 the electrocardiogram and the corresponding mechanogram of a patient are shown.
- the electrocardiogram shown in line 1 shows QRS complexes and more precisely the spontaneous or stimulated R wave at a basic rate, for example 60 pulses / min.
- the appearance of the QRS complex creates a refractory zone electric ZRE which ends more or less with the T wave, without a sufficient correlation being generally established. This refractory zone is followed by the electrically sensitive diastole LED.
- EM electromechanical coupling delay
- An isovolumetric contraction first occurs as long as the valves are not open, for the duration Cl.
- This contraction is followed by a contraction with blood ejection EJ between the opening A of the aortic valve and the opening M of the mitral valve.
- DE represents the mechanical diastole, first motive, then elastic and passive filling.
- the maximum mechanical refractory zone, during which the heart muscle is in the most contracted state, is represented by ZRMM.
- This area which corresponds to the top of the pressure curve, is, in the example shown, relatively flattened because the pressure curve was obtained by a sensor measuring the intracavitary blood pressure in the ventricle.
- an intramyocardial pressure sensor is placed in a local region or zone, the increase in local pressure is very clear and makes it possible to easily distinguish the local maximum mechanical refractory zone close to the active electrode.
- the line 1 electrocardiogram is acquired in this local region, for example preferably the myocardial region adjacent to the ventricular pacing and sensing electrode, and the curve is acquired. intramyocardial pressure also in this myocardial region. We reason hereinafter as if the curves of lines 1 and 2 in Figure 9 represented these local curves in the chosen region. It is then observed that the ZRE electrical refractory zone can partially or even completely overlap the ZRMM zone.
- an effective critical zone ZCE to target which can be equal to the ZRMM zone in the case where the electrical refractory zone ZRE ends before the start of the ZRMM zone, and which may be zero if ZRE is elongated and encompasses the duration of the ZRMM zone.
- the coupled or paired stimulation is sent during the ZCE zone.
- This one can be quite often of the order of 30 to 40 ms and, in this case, the sending, sufficiently early towards the end of ERZ, of a burst of pulses having an interval between the pulses, for example of 20 ms , will certainly cause stimulation in the targeted ZCE zone, without a negative increase in local oxygen consumption, stimulation which will produce the post-extra-systolic reinforcement expected with the smallest increase in oxygen consumption, compared to the increase in mechanical work of the RPE myocardium (PEPS). If the ZCE zone tends to narrow, the device can then advantageously reduce the interval between the burst pulses so as to guarantee that a burst pulse will fall in this ZCE zone.
- PEPS RPE myocardium
- the electronic means not allowing, in this case, to identify the stimulating pulse of the burst. Consequently, it is preferred, if the ZCE zone is less than 10 or 15 ms, not to send paired or coupled pulses. It will be the same if we observe over a certain number of cycles that the ZCE zone varies too anarchically in duration or in time.
- the ZRE zone will be detected by the use of pulse trains as described above, and the positions and durations of the ZCE zones of a plurality of cycles will be memorized, for example from 30 to 3000 cycles, to detect if the ZCE zone is roughly stable or if it has a tendency to decrease or increase and we can then intervene accordingly, this time by sending a stimulation pulse, preferably rather towards the estimated end of the ZRMM zone of the current cycle, assuming that the ZCE zone will be existing at this time.
- the ZRMM zone in an initial myocardial zone where the propagation of depolarization begins, the electrical impulse then propagating in the rest of the myocardium at the same time and at substantially equal speed as the maximum contraction, their coupling remaining sufficiently constant.
- the ZRMM zone and possibly the depolarization signals. corresponding electrics in several places and stimulate in these places during their zones ZRMM or more precisely ZCE respective.
- Line 1 represents the spontaneous rhythm, for example 90 p / mm in a person with acute heart failure.
- Line 2 represents the spontaneous pressure variation in the left ventricle generated by the spontaneous rhythm.
- Line 3 represents the electrogram of a simulated paired stimulation in this same patient, which maintains a rhythm identical or similar to that of line 1.
- Line 4 represents the resulting simulated variation of left intraventricular pressure.
- Line 5 consists of a superimposition of the real pressure differences of line 2 and simulated of line 4, the differences being hatched.
- FIG. 11 there is shown the control panel of a SIMA device according to the invention, divided into three parts 101, 102, 103.
- the panel 101 includes an atrial control sub-panel
- the panel 104 corresponding to stimulation and atrial detection electrodes and a ventricular sub-panel 105 corresponding to stimulation and ventricular detection electrodes.
- the panel 104 has three adjustment buttons, namely 108 for choosing the amplitude of the stimulation pulses, 109 for the detection sensitivity and 110 for the duration between the atrial and ventricular stimulations if the DDD mode is chosen.
- the ventricular panel 105 has three buttons 111, 112, 113 for adjusting and amplifying the ventricular pulses, the sensitivity of the ventricular detection electrode and the atrioventricular offset.
- the button 114 makes it possible to define the rhythm of orthorythmic stimulation.
- the button 106 makes it possible to implement or interrupt the stimulation and the button 107 to switch to atrial, ventricular or DDD mode.
- the panel 102 comprises the stimulation-STIO control buttons according to the invention.
- the button 115 makes it possible to implement or interrupt the STIO stimulation and the button 116 makes it possible to trigger an automatic stimulation only for a single cycle.
- Sub-panel 117 has a set of buttons, namely 118 for coupling (in percentage), 119 for coupling in ms. fixed, 120 to display the period of the basic stimulation.
- the sub-panel 121 makes it possible to choose the proportion of cycles to be stimulated.
- the sub-panel 124 has three buttons 125, 126 and 127 for defining the parameters of the pulses of the burst of inotropic stimulation pulses, namely the number of pulses in the burst by the button 125, the interval between the two consecutive pulses in the burst by the buttons 126, and the amplitude of the burst pulse (button 127).
- the emergency stop button 128 allows the immediate inotropic stimulation to be stopped.
- the lower part 103 makes it possible to display and adjust the simulation
- the part 103 comprises a screen 128 on which appear the actual and simulated electrical, mechanical curves and their juxtaposition, as shown in fig. 10.
- a sub-panel 130 displays the spontaneous values detected
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602004023411T DE602004023411D1 (en) | 2003-11-06 | 2004-10-27 | Inotroper orthorhythmischer herzstimulator |
CA002544808A CA2544808A1 (fr) | 2003-11-06 | 2004-10-27 | Stimulateur cardiaque orthorythmique inotrope |
AU2004289080A AU2004289080B2 (en) | 2003-11-06 | 2004-10-27 | Inotropic orthorythmic cardiac stimulator |
AT04805324T ATE444099T1 (de) | 2003-11-06 | 2004-10-27 | Inotroper orthorhythmischer herzstimulator |
EP04805324A EP1684853B1 (fr) | 2003-11-06 | 2004-10-27 | Stimulateur cardiaque orthorythmique inotrope |
IL175441A IL175441A0 (en) | 2003-11-06 | 2006-05-04 | Stimulateur cardiaque orthorythmique inotrope |
US11/381,690 US7917211B2 (en) | 2003-11-06 | 2006-05-04 | Inotropic orthorhythmic cardiac stimulator |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0313055A FR2861996A1 (fr) | 2003-11-06 | 2003-11-06 | Stimulateur cardiaque orthorythmique inotrope |
FR0313055 | 2003-11-06 | ||
FR0401736A FR2861997A1 (fr) | 2003-11-06 | 2004-02-20 | Stimulateur cardiaque orthorythmique inotrope |
FR0401736 | 2004-02-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005046790A2 true WO2005046790A2 (fr) | 2005-05-26 |
WO2005046790A3 WO2005046790A3 (fr) | 2005-09-22 |
Family
ID=34524993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2004/002767 WO2005046790A2 (fr) | 2003-11-06 | 2004-10-27 | Stimulateur cardiaque orthorythmique inotrope |
Country Status (9)
Country | Link |
---|---|
US (2) | US7917211B2 (fr) |
EP (2) | EP2213729A3 (fr) |
AT (1) | ATE444099T1 (fr) |
AU (1) | AU2004289080B2 (fr) |
CA (1) | CA2544808A1 (fr) |
DE (1) | DE602004023411D1 (fr) |
FR (1) | FR2861997A1 (fr) |
IL (1) | IL175441A0 (fr) |
WO (1) | WO2005046790A2 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007075321A1 (fr) | 2005-12-22 | 2007-07-05 | Cardiac Pacemakers, Inc. | Procede et appareil pour ameliorer l'efficacite cardiaque en fonction de la consommation d'oxygene myocardique |
WO2010084275A1 (fr) | 2009-01-26 | 2010-07-29 | Fred Zacouto | Procédé simplifié de reprogrammation génétique et épigénétique partielle de cellules. |
US7774057B2 (en) * | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
US7894896B2 (en) | 2005-05-13 | 2011-02-22 | Cardiac Pacemakers, Inc. | Method and apparatus for initiating and delivering cardiac protection pacing |
US8874207B2 (en) | 2005-12-23 | 2014-10-28 | Cardiac Pacemakers, Inc. | Method and apparatus for tissue protection against ischemia using remote conditioning |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US7787950B1 (en) * | 2006-11-03 | 2010-08-31 | Pacesetter, Inc. | Techniques for delivery of stem cell and related therapies to treat cardiac conditions |
US20100121307A1 (en) * | 2007-08-24 | 2010-05-13 | Microfabrica Inc. | Microneedles, Microneedle Arrays, Methods for Making, and Transdermal and/or Intradermal Applications |
US20090156921A1 (en) * | 2007-12-18 | 2009-06-18 | Huisun Wang | Cardiac ablation catheter with oxygen saturation sensor |
US9795442B2 (en) | 2008-11-11 | 2017-10-24 | Shifamed Holdings, Llc | Ablation catheters |
US8805466B2 (en) | 2008-11-11 | 2014-08-12 | Shifamed Holdings, Llc | Low profile electrode assembly |
CN104068933B (zh) | 2008-11-11 | 2017-03-15 | 施菲姆德控股有限责任公司 | 小外形的电极组件 |
US8423141B2 (en) * | 2009-01-30 | 2013-04-16 | Medtronic, Inc. | Pre-excitation stimulus timing based on mechanical event |
CN102481433B (zh) | 2009-06-24 | 2014-12-31 | 施菲姆德控股有限责任公司 | 可转向医疗输送装置 |
US9399132B2 (en) * | 2009-06-30 | 2016-07-26 | Boston Scientific Neuromodulation Corporation | Method and device for acquiring physiological data during tissue stimulation procedure |
CN102917748B (zh) | 2010-03-24 | 2015-04-01 | 施菲姆德控股有限责任公司 | 血管内组织破坏 |
US9655677B2 (en) | 2010-05-12 | 2017-05-23 | Shifamed Holdings, Llc | Ablation catheters including a balloon and electrodes |
CN103764216B (zh) | 2011-05-03 | 2016-08-17 | 施菲姆德控股有限责任公司 | 可转向输送护套 |
US8961550B2 (en) | 2012-04-17 | 2015-02-24 | Indian Wells Medical, Inc. | Steerable endoluminal punch |
WO2013169914A1 (fr) * | 2012-05-08 | 2013-11-14 | Northwestern University | Utilisation d'électrogrammes intracardiaques pour prévoir l'emplacement d'une fibrose et de nerfs du système autonome dans le cœur |
EP2684515B1 (fr) * | 2012-07-13 | 2014-12-17 | Sorin CRM SAS | Dispositif médical actif comprenant des moyens de suivi de l'état d'un patient souffrant d'un risque d'insuffisance cardiaque |
EP2882336B1 (fr) | 2012-08-09 | 2019-06-26 | University of Iowa Research Foundation | Systèmes de cathéter de perforation à travers une structure de tissu |
US9918788B2 (en) * | 2012-10-31 | 2018-03-20 | St. Jude Medical, Atrial Fibrillation Division, Inc. | Electrogram-based ablation control |
CN105228547B (zh) | 2013-04-08 | 2019-05-14 | 阿帕玛医疗公司 | 心脏消融导管 |
US10098694B2 (en) | 2013-04-08 | 2018-10-16 | Apama Medical, Inc. | Tissue ablation and monitoring thereof |
US10349824B2 (en) | 2013-04-08 | 2019-07-16 | Apama Medical, Inc. | Tissue mapping and visualization systems |
WO2015103574A1 (fr) | 2014-01-06 | 2015-07-09 | Iowa Approach Inc. | Appareil et procédés pour ablation de dénervation rénale |
EP3495018B1 (fr) | 2014-05-07 | 2023-09-06 | Farapulse, Inc. | Appareil d'ablation de tissus sélectifs |
EP3154464A4 (fr) | 2014-06-12 | 2018-01-24 | Iowa Approach Inc. | Procédé et appareil d'ablation de tissu rapide et sélective à l'aide de refroidissement |
WO2015192027A1 (fr) | 2014-06-12 | 2015-12-17 | Iowa Approach Inc. | Procédé et appareil d'ablation transurétrale de tissu rapide et sélective |
WO2016060983A1 (fr) | 2014-10-14 | 2016-04-21 | Iowa Approach Inc. | Procédé et appareil pour l'ablation rapide et sûre d'une veine cardiopulmonaire |
JP6797131B2 (ja) | 2015-03-27 | 2020-12-09 | カリラ メディカル インコーポレイテッド | 操向可能な医療器具、システムおよび使用方法 |
EP3285849A4 (fr) | 2015-04-24 | 2018-12-26 | Shifamed Holdings, LLC | Dispositifs médicaux orientables, systèmes et leurs procédés d'utilisation |
CA3003045A1 (fr) | 2015-11-09 | 2017-05-18 | Shifamed Holdings, Llc | Ensembles de direction pour dispositifs medicaux et procedes d'utilisation |
WO2017087549A1 (fr) | 2015-11-16 | 2017-05-26 | Apama Medical, Inc. | Dispositifs délivrant de l'énergie |
US10172673B2 (en) | 2016-01-05 | 2019-01-08 | Farapulse, Inc. | Systems devices, and methods for delivery of pulsed electric field ablative energy to endocardial tissue |
US10130423B1 (en) | 2017-07-06 | 2018-11-20 | Farapulse, Inc. | Systems, devices, and methods for focal ablation |
US10660702B2 (en) | 2016-01-05 | 2020-05-26 | Farapulse, Inc. | Systems, devices, and methods for focal ablation |
US20170189097A1 (en) | 2016-01-05 | 2017-07-06 | Iowa Approach Inc. | Systems, apparatuses and methods for delivery of ablative energy to tissue |
EP3471631A4 (fr) | 2016-06-16 | 2020-03-04 | Farapulse, Inc. | Systèmes, appareils et procédés de distribution de fil de guidage |
US10945661B2 (en) * | 2017-04-21 | 2021-03-16 | Physio-Control, Inc. | Physiological feedback systems and methods |
US9987081B1 (en) | 2017-04-27 | 2018-06-05 | Iowa Approach, Inc. | Systems, devices, and methods for signal generation |
US10617867B2 (en) | 2017-04-28 | 2020-04-14 | Farapulse, Inc. | Systems, devices, and methods for delivery of pulsed electric field ablative energy to esophageal tissue |
EP3681391A1 (fr) | 2017-09-12 | 2020-07-22 | Farapulse, Inc. | Systèmes, appareils, et méthodes pour l'ablation focale ventriculaire |
CN112118798A (zh) | 2018-05-07 | 2020-12-22 | 法拉普尔赛股份有限公司 | 用于过滤由脉冲电场消融诱导的高压噪声的系统、设备和方法 |
WO2019217433A1 (fr) | 2018-05-07 | 2019-11-14 | Farapulse, Inc. | Systèmes, appareils, et méthodes d'administration d'énergie d'ablation à un tissu |
WO2019217300A1 (fr) | 2018-05-07 | 2019-11-14 | Farapulse, Inc. | Cathéter d'ablation épicardiale |
CN108888263B (zh) * | 2018-05-22 | 2020-10-30 | 郑州大学 | 一种基于几何形态群组特征的r波检测方法 |
JP2022501112A (ja) | 2018-09-20 | 2022-01-06 | ファラパルス,インコーポレイテッド | 心内膜組織へのパルス電界アブレーションエネルギーの送達のためのシステム、装置、および方法 |
US10625080B1 (en) | 2019-09-17 | 2020-04-21 | Farapulse, Inc. | Systems, apparatuses, and methods for detecting ectopic electrocardiogram signals during pulsed electric field ablation |
US11497541B2 (en) | 2019-11-20 | 2022-11-15 | Boston Scientific Scimed, Inc. | Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses |
US11065047B2 (en) | 2019-11-20 | 2021-07-20 | Farapulse, Inc. | Systems, apparatuses, and methods for protecting electronic components from high power noise induced by high voltage pulses |
US10842572B1 (en) | 2019-11-25 | 2020-11-24 | Farapulse, Inc. | Methods, systems, and apparatuses for tracking ablation devices and generating lesion lines |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1237702A (fr) | 1953-07-11 | 1960-08-05 | Perfectionnements aux appareils électro-médicaux | |
US3857399A (en) | 1970-03-24 | 1974-12-31 | F Zacouto | Heart pacer |
US3939844A (en) | 1973-10-18 | 1976-02-24 | Michel Pequignot | Method and apparatus for stimulating a heart to eliminate rhythmic abnormalities, especially tachycardias |
US4052991A (en) | 1970-03-24 | 1977-10-11 | Fred Zacouto | Method of stimulating the heart |
US5213098A (en) | 1991-07-26 | 1993-05-25 | Medtronic, Inc. | Post-extrasystolic potentiation stimulation with physiologic sensor feedback |
US5306293A (en) | 1990-11-23 | 1994-04-26 | Fred Zacouto | Device for the prevention of cardiac failures |
WO2002053026A2 (fr) | 2000-12-28 | 2002-07-11 | Medtronic, Inc. | Dispositif medical implantable destine a traiter un dysfonctionnement cardiaque mecanique par stimulation electrique |
WO2003020364A2 (fr) | 2001-08-28 | 2003-03-13 | Medtronic, Inc. | Dispositif medical implantable permettant de traiter un dysfonctionnement cardiaque mecanique par stimulation electrique |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR651632A (fr) | 1927-07-20 | 1929-02-21 | Cie Des Metaux Overpelt Lommel | Perfectionnements aux appareils continus à vent ou gaz aspiré ou soufflé |
US4052911A (en) | 1973-05-18 | 1977-10-11 | Incom International Inc. | Cable core conduit |
US4280502A (en) * | 1979-08-08 | 1981-07-28 | Intermedics, Inc. | Tachycardia arrester |
CA1327838C (fr) | 1988-06-13 | 1994-03-15 | Fred Zacouto | Dispositif implantable de protection contre les affections liees a la coagulation sanguine |
US5989244A (en) * | 1994-11-15 | 1999-11-23 | Gregory; Kenton W. | Method of use of a sheet of elastin or elastin-based material |
US6087552A (en) * | 1994-11-15 | 2000-07-11 | Sisters Of Providence Of Oregon | Method of producing fused biomaterials and tissue |
US6775574B1 (en) * | 1997-11-07 | 2004-08-10 | Medtronic, Inc. | Method and system for myocardial infarction repair |
US6206914B1 (en) * | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
BR0012099A (pt) * | 1999-06-30 | 2003-07-29 | Advanced Cell Tech Inc | Transferência citoplásmica para de-diferenciar células recipientes |
AU2002230999A1 (en) * | 2000-12-21 | 2002-07-01 | Medtronic, Inc. | Electrically responsive promoter system |
WO2002072191A2 (fr) * | 2001-03-12 | 2002-09-19 | Chachques Juan C | Procédé de réalisation d'un support cardiaque cellulaire dynamique |
-
2004
- 2004-02-20 FR FR0401736A patent/FR2861997A1/fr active Pending
- 2004-10-27 CA CA002544808A patent/CA2544808A1/fr not_active Abandoned
- 2004-10-27 WO PCT/FR2004/002767 patent/WO2005046790A2/fr active Application Filing
- 2004-10-27 EP EP09168525A patent/EP2213729A3/fr not_active Withdrawn
- 2004-10-27 AU AU2004289080A patent/AU2004289080B2/en not_active Ceased
- 2004-10-27 DE DE602004023411T patent/DE602004023411D1/de active Active
- 2004-10-27 EP EP04805324A patent/EP1684853B1/fr not_active Not-in-force
- 2004-10-27 AT AT04805324T patent/ATE444099T1/de not_active IP Right Cessation
-
2006
- 2006-05-04 US US11/381,690 patent/US7917211B2/en not_active Expired - Fee Related
- 2006-05-04 IL IL175441A patent/IL175441A0/en unknown
- 2006-09-12 US US11/531,158 patent/US20070078507A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1237702A (fr) | 1953-07-11 | 1960-08-05 | Perfectionnements aux appareils électro-médicaux | |
US3857399A (en) | 1970-03-24 | 1974-12-31 | F Zacouto | Heart pacer |
US4052991A (en) | 1970-03-24 | 1977-10-11 | Fred Zacouto | Method of stimulating the heart |
US3939844A (en) | 1973-10-18 | 1976-02-24 | Michel Pequignot | Method and apparatus for stimulating a heart to eliminate rhythmic abnormalities, especially tachycardias |
US5306293A (en) | 1990-11-23 | 1994-04-26 | Fred Zacouto | Device for the prevention of cardiac failures |
US5213098A (en) | 1991-07-26 | 1993-05-25 | Medtronic, Inc. | Post-extrasystolic potentiation stimulation with physiologic sensor feedback |
WO2002053026A2 (fr) | 2000-12-28 | 2002-07-11 | Medtronic, Inc. | Dispositif medical implantable destine a traiter un dysfonctionnement cardiaque mecanique par stimulation electrique |
WO2003020364A2 (fr) | 2001-08-28 | 2003-03-13 | Medtronic, Inc. | Dispositif medical implantable permettant de traiter un dysfonctionnement cardiaque mecanique par stimulation electrique |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7894896B2 (en) | 2005-05-13 | 2011-02-22 | Cardiac Pacemakers, Inc. | Method and apparatus for initiating and delivering cardiac protection pacing |
US8396552B2 (en) | 2005-05-13 | 2013-03-12 | Cardiac Pacemakers, Inc. | Method and apparatus for initiating and delivering cardiac protection pacing |
US7774057B2 (en) * | 2005-09-06 | 2010-08-10 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
US8538520B2 (en) | 2005-09-06 | 2013-09-17 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression for cardiac protection |
WO2007075321A1 (fr) | 2005-12-22 | 2007-07-05 | Cardiac Pacemakers, Inc. | Procede et appareil pour ameliorer l'efficacite cardiaque en fonction de la consommation d'oxygene myocardique |
JP2009521263A (ja) * | 2005-12-22 | 2009-06-04 | カーディアック ペースメイカーズ, インコーポレイテッド | 心筋酸素消費量に基づいて心臓効率を向上させる方法及び装置 |
US9155896B2 (en) | 2005-12-22 | 2015-10-13 | Cardiac Pacemakers, Inc. | Method and apparatus for improving cardiac efficiency based on myocardial oxygen consumption |
US8874207B2 (en) | 2005-12-23 | 2014-10-28 | Cardiac Pacemakers, Inc. | Method and apparatus for tissue protection against ischemia using remote conditioning |
WO2010084275A1 (fr) | 2009-01-26 | 2010-07-29 | Fred Zacouto | Procédé simplifié de reprogrammation génétique et épigénétique partielle de cellules. |
Also Published As
Publication number | Publication date |
---|---|
AU2004289080A1 (en) | 2005-05-26 |
US20070078507A1 (en) | 2007-04-05 |
IL175441A0 (en) | 2006-09-05 |
AU2004289080B2 (en) | 2011-04-28 |
CA2544808A1 (fr) | 2005-05-26 |
EP2213729A3 (fr) | 2011-03-02 |
FR2861997A1 (fr) | 2005-05-13 |
US20060247701A1 (en) | 2006-11-02 |
WO2005046790A3 (fr) | 2005-09-22 |
DE602004023411D1 (en) | 2009-11-12 |
EP1684853B1 (fr) | 2009-09-30 |
ATE444099T1 (de) | 2009-10-15 |
US7917211B2 (en) | 2011-03-29 |
EP2213729A2 (fr) | 2010-08-04 |
EP1684853A2 (fr) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1684853B1 (fr) | Stimulateur cardiaque orthorythmique inotrope | |
EP0487429B1 (fr) | Dispositif de prévention des défaillances cardiaques | |
DE60030334T2 (de) | Vorrichtung zur myokardwiederherstellung bei myokard-infarkt | |
US11905510B2 (en) | Methods and systems for activating cells to treat aging | |
Holmes et al. | Making better scar: emerging approaches for modifying mechanical and electrical properties following infarction and ablation | |
Lancaster et al. | Human induced pluripotent stem cell–derived cardiomyocyte patch in rats with heart failure | |
JP6509882B2 (ja) | 筋細胞パッチおよびその使用 | |
Lancaster et al. | An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure | |
Livneh et al. | Extracorporeal acute cardiac pacing by high intensity focused ultrasound | |
US20080280341A1 (en) | System And Method For Local Field Stimulation | |
EP3373996B1 (fr) | Méthode pour la production, l'utilisation at l'administration de cellules souches activées | |
EP2914300B1 (fr) | Canaux pour ions sensibles à la lumière pour l'induction de l'activité cardiaque | |
US8175704B2 (en) | Techniques for delivery of stem cell and related therapies to treat cardiac conditions | |
US20080280339A1 (en) | Cell Training For Local Field Stimulation | |
FR2861996A1 (fr) | Stimulateur cardiaque orthorythmique inotrope | |
EP1885846A2 (fr) | Système et procédé de traitement génétique et epigénétique | |
WO2014068566A1 (fr) | Pompes sensibles à la lumière pour freiner l'activité cardiaque | |
WO2024006673A1 (fr) | Système et procédé de maturation de cellules souches et d'organes | |
Nĕmec et al. | Optical Mapping: Its Impact on Understanding Arrhythmia Mechanisms | |
Dalamanga et al. | CRT48: BENEFICIAL EFFECTS OF BIVENTRICULAR PACING ON INTERVENTRICULAR AND INTRAVENTRICULAR SYNCHRONIZATION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 175441 Country of ref document: IL Ref document number: 2544808 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004805324 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004289080 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2004289080 Country of ref document: AU Date of ref document: 20041027 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004289080 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2004805324 Country of ref document: EP |